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A B S T R A C T
Background
Self-monitoring of blood glucose (SMBG) has been found to be effective for patients with type 1 diabetes and for patients with type 2
diabetes using insulin. There is much debate on the effectiveness of SMBG as a tool in the self-management for patients with type 2
diabetes who are not using insulin.
Objectives
To assess the effects of SMBG in patients with type 2 diabetes mellitus who are not using insulin.
Search methods
Multiple electronic bibliographic and ongoing trial databases were searched supplemented with handsearches of references of retrieved
articles (date of last search: 07 July 2011).
Selection criteria
Randomised controlled trials investigating the effects of SMBG compared with usual care, self-monitoring of urine glucose (SMUG) or
both in patients with type 2 diabetes who where not using insulin. Studies that used glycosylated haemoglobin A1c (HbA1c) as primary
outcome were eligible for inclusion.
Data collection and analysis
Two authors independently extracted data from included studies and evaluated the studies’ risk of bias. Data from the studies were
compared to decide whether they were sufficiently homogeneous to pool in a meta-analysis. Primary outcomes were HbA1c , health-
related quality of life, well-being and patient satisfaction. Secondary outcomes were fasting plasma glucose level, hypoglycaemic episodes,
morbidity, adverse effects and costs.
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Main results
Twelve randomised controlled trials were included and evaluated outcomes in 3259 randomised patients. Intervention duration ranged
from 6 months (26 weeks) to 12 months (52 weeks). Nine trials compared SMBG with usual care without monitoring, one study
compared SMBG with SMUG, one study was a three-armed trial comparing SMBG and SMUG with usual care and one study was
a three-armed trial comparing less intensive SMBG and more intensive SMBG with a control group. Seven out of 11 studies had a
low risk of bias for most indicators. Meta-analysis of studies including patients with a diabetes duration of one year or more showed a
statistically significant SMBG induced decrease in HbA1c at up to six months follow-up (-0.3; 95% confidence interval (CI) -0.4 to -
0.1; 2324 participants, nine trials), yet an overall statistically non-significant SMBG induced decrease was seen at 12 month follow-
up (-0.1; 95% CI -0.3 to 0.04; 493 participants, two trials). Qualitative analysis of the effect of SMBG on well-being and quality of
life showed no effect on patient satisfaction, general well-being or general health-related quality of life. Two trials reported costs of
self-monitoring: One trial compared the costs of self-monitoring of blood glucose with self-monitoring of urine glucose based on nine
measurements per week and with the prices in US dollars for self-monitoring in 1990. Authors concluded that total costs in the first
year of self-monitoring of blood glucose, with the purchase of a reflectance meter were 12 times more expensive than self-monitoring of
urine glucose ($481 or 361 EURO [11/2011 conversion] versus $40 or 30 EURO [11/2011 conversion]). Another trial reported a full
economical evaluation of the costs and effects of self-monitoring. At the end of the trial, costs for the intervention were £89 (104 EURO
[11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive
self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group. Higher losses to
follow-up in the more intensive self-monitoring group were responsible for the difference in costs, compared to the less intensive self-
monitoring group.
There were few data on the effects on other outcomes and these effects were not statistically significant. None of the studies reported
data on morbidity.
Authors’ conclusions
From this review, we conclude that when diabetes duration is over one year, the overall effect of self-monitoring of blood glucose on
glycaemic control in patients with type 2 diabetes who are not using insulin is small up to six months after initiation and subsides after
12 months. Furthermore, based on a best-evidence synthesis, there is no evidence that SMBG affects patient satisfaction, general well-
being or general health-related quality of life. More research is needed to explore the psychological impact of SMBG and its impact on
diabetes specific quality of life and well-being, as well as the impact of SMBG on hypoglycaemia and diabetic complications.
P L A I N L A N G U A G E S U M M A R Y
Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Self-monitoring of blood glucose has been found to be effective as a tool in the self-management of patients’ glucose levels in people
with type 1 diabetes and people with type 2 diabetes using insulin therapy. Patients can use the glucose values to adjust their insulin
doses. It is hypothesized that patients with type 2 diabetes who are not using insulin might use the glucose values to adjust their diet
and ’lifestyle’. However, there is no consensus on the effect of self-monitoring of blood glucose for type 2 diabetes patients not using
insulin. In this systematic review update six new randomised controlled trials were added to the six trials that had been included in
the original review. For the comparison of the effect of self-monitoring versus no self-monitoring in patients with a diabetes duration
of one year or more 2324 patients with a six months follow-up and 493 patients with a 12 months follow-up were available. Pooled
results of studies including patients diagnosed with type 2 diabetes for at least one year show that self-monitoring of blood glucose has
a minimal effect in improving glucose control at six months, which disappears after 12 months follow-up. The clinical benefit resulting
from this effect is limited.
Two studies reported costs of self-monitoring: One study compared the costs of self-monitoring of blood glucose with self-monitoring
of urine glucose based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990. They concluded
that total costs in the first year of self-monitoring of blood glucose, with the purchase of a reflectancemeter were 12 timesmore expensive
than self-monitoring of urine glucose ($481 or 361 EURO [11/2011 conversion] versus $40 or 30 EURO [11/2011 conversion]).
Another study reported a full economical evaluation of the costs and effects of self-monitoring. At the end of the trial, costs for the
intervention were £89 (104 EURO [11/2011 conversion]) for standardized usual care (control group), £181 (212 EURO [11/2011
conversion]) for the less intensive self-monitoring group and £173 (203 EURO [11/2011 conversion]) for the more intensive self-
monitoring group.
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We did not find good evidence for an effect on general health-related quality of life, general well-being, patient satisfaction, or on the
decrease of the number of hypoglycaemic episodes. However, hypoglycaemic episodes were more often reported in the self-monitoring
blood glucose groups than in the control groups (four studies). Because patients in the self-monitoring blood glucose groups can use
their device to confirm both periods of asymptomatic and symptomatic hypoglycaemic episodes, this is according to expectations.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Self-monitoring of blood glucose compared to control or self-monitoring of urine glucose for type 2 diabetes mellitus
Patient or population: Patients with type 2 diabetes mellitus
Intervention: Self-monitoring of blood glucose (SMBG)
Comparison: Control, self-monitoring of urine glucose (SMUG)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control / SMUG SMBG
Morbidity See comment See comment Not estimable See comment See comment Not investigated
Health-related quality of
life
Follow-up: 6 to 12
months
See comment See comment Not estimable 523
(3 studies)
⊕⊕⊕©
moderate1
Probably no clinically rele-
vant differences
Well-being
Follow-up: 6 to 12
months
See comment See comment Not estimable 928
(4 studies)
⊕⊕⊕©
moderate1
Probably no clinically rele-
vant differences
Patient satisfaction
Follow-up: 6 to 12
months
See comment See comment Not estimable 928
(4 studies)
⊕⊕⊕©
moderate1
Probably no clinically rele-
vant differences
Hypoglycaemic
episodes
Follow-up: 6 to 12
months
See comment See comment Not estimable 2492
(6 studies)
⊕⊕⊕©
moderate2
Probably no clinically rele-
vant differences
Costs
Follow-up: 6 to 12
months
See comment See comment Not estimable 514
(2 studies)
⊕⊕⊕©
moderate3
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HbA1c [%]
Follow-up: 6 to 12
months
-0.3 (-0.4 to -0.1) at 6 months
-0.1 (-0.3 to 0.04) at 12 months
-0.5 (-0.9 to -0.1) at 12 months*
-0.2 (-1 to 0.6) at 6 months**
2324 (9 studies)
493 (2 studies)
⊕⊕⊕©
moderate4
Results refer to subgroup-
analyses
* newly diagnosed dia-
betes
** SMBG vs SMUG
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Because few included trials reported outcomes on health-related quality of life, well-being and patient satisfaction and self-reported
measures varied substantially, presenting a general effect estimate was not possible and interpretation of best-evidence synthesis is
difficult. Similar effects on similar sub-scales or dimensions in similar directions suggested a clinical non-relevant effect of SMBG on
general (health-related) quality of life and well-being. Since all trials that measured patient-satisfaction did not report an SMBG related
effect, this is considered clinical relevant as well.
2 Data for adverse events could not be extracted separately for intervention and control groups. Studies reported occurrence of
hypoglycaemia by recording asymptomatic or symptomatic hypoglycaemic episodes and/or by using detailed graded definitions. Due
to substantial variation in definitions of hypoglycaemia, high risk of bias regarding occurrence and severity of hypoglycaemia between
studies exists. Experiencing hypoglycaemic events can be confirmed with SMBG. Therefore, it is in the line of expectation that more
frequent hypoglycaemic events seem to have been reported when using SMBG.
3 Only two trial, Allen 1990 and the DiGEM trial 2007 reported outcomes on approximate costs of self-monitoring. Allen 1990 compared
the costs of SMBG with SMUG based on nine measurements per week and with the prices in US dollars for self-monitoring in 1990.
They concluded that total costs in the first year of SMBG, with the purchase of a reflectance meter were 12 times more expensive than
SMUG (SMBG = $481 or 361 EURO [11/2011 conversion]; SMUG = $40 or 30 EURO [11/2011 conversion]). In the DiGEM trial 2007
a full economical analysis was performed. At the end of the trial, costs for the intervention were £89 (104 EURO [11/2011 conversion])
for standardized usual care (control group), £181 (212 EURO [11/2011 conversion]) for the less intensive self-monitoring group and
£173 (203 EURO [11/2011 conversion]) for the more intensive self-monitoring group. Higher losses to follow-up in the more intensive
self-monitoring group were responsible for the difference in costs, compared to the less intensive self-monitoring group.
4 Different levels of probability and estimates of outcome variables of included studies might account for differences in presented
subgroups. In addition, differences in requested monitoring frequency, glycosylated haemoglobin A1c (HbA1c) level at baseline and
SMBG and diabetes education may have contributed to the differences as well.
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B A C K G R O U N D
This is an update of a previous Cochrane review (Welschen
2005a) investigating the effects of self-monitoring of blood glu-
cose (SMBG) in patients with type 2 diabetes who are not using
insulin.
Description of the condition
“Diabetes mellitus is a metabolic disorder resulting from a defect
in insulin secretion, insulin action, or both. A consequence of this
is chronic hyperglycaemia (that is elevated levels of plasma glucose)
with disturbances of carbohydrate, fat and protein metabolism.
Long-term complications of diabetes mellitus include retinopathy,
nephropathy and neuropathy. The risk of cardiovascular disease
and cancer is increased. For a detailed overviewof diabetesmellitus,
please see under ’Additional information’ in the information on
the Metabolic and Endocrine Disorders Group in The Cochrane
Library (see ’About’, ’Cochrane Review Groups (CRGs)’). For an
explanation of methodological terms, see themain Glossary in The
Cochrane Library.”
Description of the intervention
Diabetes care is complex and requires patients to take an active
role in the management of their disease. Currently, adequate and
continuingmedical care aiming at preventing acute complications,
diminishing risk of long-term complications as well as patient self-
management education are considered standard in the care for type
2 diabetes patients (ADA 2010). Patients who improve their skills
and confidence to manage their diabetes and who take a central
role in the management of their disease improve their outcomes
(Olivarius 2001; Piatt 2006; Rothman 2005; Wagner 2001).
Hence, self-management skills have an important role in optimal
diabetes control. They enable patients to control their glucose
level by recognizing, understanding and act on symptoms related
to type 2diabetes. Self-monitoring of blood glucose levels (SMBG)
is presented as such a self-management skill and is therefore rec-
ommended as an element in self-management education (ADA
2010). The hypothesis that self-monitoring of glucose empowers
the patient by its feedback, is based on the principles of the self-
regulation theory (Leventhal 1980; Leventhal 1997). This model
proposes that individuals construct schematic perceptions of ill-
ness and health-threatening conditions according to their avail-
able sources of information. These illness perceptions determine
how patients respond to their illness or related threats and are
mediators in the willingness and ability to take action. Feedback
on the illness condition allows adaptation of illness perceptions,
which eventually may lead to changes in ’lifestyle’, quality of life
and subsequently glycaemic control. Furthermore, it is assumed
that SMBG may improve adherence to pharmacological treat-
ment and motivate patients to make appropriate lifestyle changes
(Fontbonne 1989; Karter 2001). Collecting data of glucose levels
on different time points and its feedback allows the timely identi-
fication of high and low blood glucose levels and might help pa-
tients to a better understanding of day to day variation in glucose
levels. Provided that the patient is informed how to interpret the
results and what actions to take, self-monitoring information can
help in making adjustments in direct interacting medication (in-
sulin dosages) and ’lifestyle’. SMBG has been found to be effec-
tive for patients with type 1 diabetes (Bode 1999; DCCT 1993
) and patients with type 2 diabetes who are using insulin (Karter
2001; Nathan 1996). However, consensus on the effectiveness
of SMBG for the self-management of patients with non-insulin
treated type 2 diabetes still remains inconclusive (Davidson 2010;
Kempf 2008; Klonoff 2008; Kolb 2010; O’Kane 2009). This can
be attributed to a lack of comparability between published trials.
Moreover, methodological limitations and poor quality of several
performed trials investigating SMBG might have had an impact
on the observed effectiveness of SMBG (Welschen 2005a).
Why it is important to do this review
Previous reviews and meta-analyses
The present review is an update of theCochrane review performed
by Welschen et al in 2005 (Welschen 2005a). In this review, sub-
stantial clinical heterogeneity between included trials was noted.
Consequently, qualitative analyses were performed and it was con-
cluded that self-monitoring of blood glucose might be effective
in improving glycaemic control in patients with type 2 diabetes
who are not using insulin. The same systematic review has been
published inDiabetes Carewith the addition of ameta-analysis, on
request of the editor (Davidson 2005a; Kleefstra 2005; Welschen
2005b). In the meta-analysis, the overall effect of SMBG was a
statistically significant and clinically relevant decrease of 0.39% in
HbA1c in favour of SMBG compared with control groups. Since
then, 11 other reviews on the effect of SMBG in patients with
type 2 diabetes not using insulin have been published. Nine re-
views included RCT’s only (Allemann 2009; Clar 2010; Jansen
2006; Kleefstra 2009; McIntosh 2010; Poolsup 2008; Poolsup
2009; Sarol 2005; Towfigh 2008), one included cross-sectional,
longitudinal and (non)randomised trials (McAndrew 2007) and
two combined observational studies and RCT’s (McGeoch 2007;
St John 2010). In all reviews, change in HbA1c was the pri-
mary outcome measure. Seven reviews performed a meta-anal-
ysis (Allemann 2009; Clar 2010; Jansen 2006; McIntosh 2010;
Poolsup 2008; Poolsup 2009; Sarol 2005; St John 2010; Towfigh
2008) with HbA1c varying from -0.42% to -0.16% in favour
of SMBG versus no-SMBG. Three reviews performed qualitative
analyses only and concluded similar to Welschen et al (Welschen
2005a) that SMBG might be effective in glycaemic control but
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that the heterogeneity in design and quality between trials compli-
cated drawing an overall conclusion on the effectiveness of SMBG
(Kleefstra 2009; McAndrew 2007; McGeoch 2007).
Since the publication of our first review new studies have been
published, possibly with good or improved methodological qual-
ity and design. We performed this update in order to explore if
these new trials provide new evidence of the effect of SMBG on
glycaemic control in patients not requiring insulin. In addition, if
possible, an estimation of the effect of SMBG on glycaemic con-
trol in patients with type 2 diabetes not requiring insulin will be
obtained. Furthermore, assessment of risk of bias of included trials
illustrate limitations or enhance strengths of the studies.
O B J E C T I V E S
To assess the effects of self-monitoring of blood glucose in patients
with type 2 diabetes mellitus who are not using insulin.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled clinical trials
(RCTs).
Types of participants
Patients diagnosed with type 2 diabetes and who are not using
insulin therapy. To be consistent with changes in classification
and diagnostic criteria of diabetes mellitus through the years, the
diagnosis should be established using the standard criteria valid
at the time of the beginning of the trial (for example ADA 1999;
ADA 2008; WHO 1998). Ideally, diagnostic criteria should have
been described. If necessary, we used authors’ definition of (type
2) diabetes.
Types of interventions
Studies describing self-monitoring of blood glucose (SMBG) as
primary intervention compared to control are investigated. Studies
concerning the comparison between SMBG and self-monitoring
of urine glucose (SMUG)were included as well (SMUG as control
group).
Types of outcome measures
Primary outcomes
• glycaemic control measured by glycated haemoglobin
concentration A1c (HbA1c-level);
• health-related quality of life, well-being (e.g. by using the
SF 36 (Ware 1992) or the well-being questionnaire (Bradley
1994a));
• patient satisfaction (e.g. by using the Diabetes Treatment
Satisfaction Questionnaire (DTSQ) (Bradley 1994b)).
Secondary outcomes
• fasting plasma glucose level;
• hypoglycaemic episodes;
• morbidity;
• adverse effects;
• costs.
Co-variates thought to be effect modifiers
• baseline glycaemic control;
• change in hypoglycaemic medications;
• duration of diabetes at baseline;
• age;
• compliance to the intervention.
Timing of outcome assessment
• short-term: up to six months of follow-up;
• medium-term: between six and twelve months of follow-up;
• long-term: twelve months or more after start of follow-up.
Search methods for identification of studies
Electronic searches
Electronic search strategies were used to identify relevant RCT’s
and reviews or meta-analyses (for identification of additional eli-
gible trials).
We used the following sources for the identification of trials:
• The Cochrane Library (issue 3, 2011);
• MEDLINE (until July 2011);
• EMBASE (until July 2011);
• PsycINFO (until July 2011).
We also searched databases of ongoing trials: ’Current Controlled
Trials’ (www.controlled-trials.com - with links to other databases
of ongoing trials).
For detailed search strategies please see under Appendix 1.
Additional keywords of relevance could have been detected during
any of the electronic or other searches. If this was the case, we
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would havemodified the electronic search strategies to incorporate
these terms. Studies published in any language were included.
Searching other resources
We tried to identify additional studies by searching the reference
lists of included trials and (systematic) reviews, meta-analyses and
health technology assessment reports noticed.
Data collection and analysis
Selection of studies
The search for publications were performed by one of the review
authors (IR) supported by theCochraneMetabolic and Endocrine
Disorders’ trials search coordinator. The MeSH terms and search
strategy used were agreed upon and tested by two review authors
(IR, UM).
Studies were selected for full text reading in three steps:
Step 1
Two review authors (UM, LW) independently made a selection of
the titles of the identified references that corresponded with the
criteria for inclusion in this review stated above. If the title did not
provide enough information to decide whether or not to include
the trial in the selection, or no consensus could be made based on
the title alone it was selected as well.
Step 2
All abstracts of selected titles were independently read (UM, LW).
Full-text articles were retrieved from all abstracts potentially eli-
gible for inclusion. In addition, if there was no abstract available
the full article was retrieved.
Step 3
All selected full-text articles were read and selected if they met the
criteria for including studies in the review.
Studies were excluded (step 2 and 3) if both review authors (UM,
LW) agreed that the study did not meet the criteria for including
studies in the review. A third party resolved possible differences in
opinion (SB). An adapted PRISMA (preferred reporting items for
systematic reviews andmeta-analyses) flow-chart of study selection
(Figure 1) is attached (Liberati 2009). Interrater agreement for
selection of potentially relevant studies was measured using the
kappa statistic (Cohen 1960). In the case of duplicate publications
and subsequent papers of a primary study, we tried to maximise
yield of information by simultaneous evaluation of all available
data. In cases of doubt, the original publication (usually the oldest
version) obtained priority.
Figure 1. Study flow diagram.
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Data extraction and management
We used data concerning details of study design, intervention and
outcomes employing a standardized extraction form and included
the following items.
• General information (authors, title, details of journal, year
of publication).
• Trial characteristics (study duration, design, methods,
geographical region, temporal setting, sequence generation,
allocation concealment, randomisation).
• Participants (total number per group, baseline
characteristics).
• Interventions (specific details of intervention/control
group).
• Outcomes (primary and secondary outcomes, timing of the
outcome assessment).
• Results (number of participants analysed per group,
dropouts/missing participants, summary data for each group, all
available results on outcomes).
• Notes (any information reported that can be important;
e.g. conflicts of interests).
A pilot test, using two trials excluded from the review preceded
the data extraction of the selected RCT’s. This test was likely to
identify data that were not needed or missing to optimise the data
extraction sheet.
Data extraction and data entry was performed independently by
two review authors (UM, LW). Any discrepancies between authors
were resolved by discussion. If necessary a third review author
(SB) was consulted for the final decision. We sought any relevant
missing information on the trial from the original author(s) of the
article, if required.
Assessment of risk of bias in included studies
Two review authors (UM, LW) assessed each trial independently.
Possible disagreement were resolved by consensus, or with consul-
tation of a third party in case of disagreement. Interrater agreement
for key bias indicators (e.g. allocation concealment, incomplete
outcome data) was calculated using the kappa statistic (Cohen
1960). In cases of disagreement, the rest of the group was con-
sulted and a judgement was made based on consensus. A pilot,
using two trials excluded from the review, preceded the assessment
of risk of bias of the RCTs.
The results and the rationale for the decision are presented in a
methodological quality graph, summary and table. No trials were
excluded based on the assessment of risk of bias.
The risk of bias in included studies and the internal validity of
included studies was assessed with the Cochrane Collaboration’s
recommended ’Risk of bias’ tool (Higgins 2009). With this tool, a
study’s risk on selection-, performance-, attrition-, detection-, and
reporting bias can be critically evaluated and judged.
We used the following criteria:
• sequence generation (was the allocation sequence
adequately generated?);
• allocation concealment (was the allocation adequately
concealed?);
• blinding of participants, personnel and outcome assessors
(was knowledge of the allocated intervention adequately
prevented during the study?);
• incomplete outcome data (were incomplete outcome data
adequately addressed?);
• selective outcome reporting (were reports of the study free
of suggestion of selective outcome reporting?);
• other sources of bias (was the study apparently free of other
problems that could put it at a high risk of bias?
Measures of treatment effect
Dichotomous data were expressed as odds ratio (OR) or risk ratio
(RR) with 95% confidence intervals (CI). Continuous were ex-
pressed as differences in means (MD) with 95% CI.
Unit of analysis issues
We took into account the level at which randomisation occurred,
such as cross-over trials, cluster-randomised trials and multiple
observations for the same outcome.
Dealing with missing data
We obtained relevant missing data from authors, if feasible and
carefully performed evaluation of important numerical data such
as screened, eligible and randomised patients as well as intention-
to-treat (ITT) and per-protocol (PP) population. We investigated
attrition rates such as drop-outs, losses to follow-up andwithdrawn
study participants.
Assessment of heterogeneity
In the event of substantial clinical-, methodological-, or statistical
heterogeneity, study results were not reported as meta-analytically
pooled effect estimates. We identified heterogeneity by visual in-
spection of the forest plots, by using a standard Chi2 test and a
significance level of α = 0.1, in view of the low power of this test.
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We specifically examined heterogeneity with the I2 statistic quan-
tifying inconsistency across studies to assess the impact of hetero-
geneity on themeta-analysis (Higgins 2002; Higgins 2003), where
an I2 statistic of 75% and more indicates a considerable level of
inconsistency (Higgins 2009).
When heterogeneity was found, we attempted to determine po-
tential reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
We planned to use funnel plots to assess for the potential existence
of small study bias. There are a number of explanations for the
asymmetry of a funnel plot (Sterne 2001). Therefore, we carefully
interpreted results (Lau 2006). Due to small number of included
studies we did not employ funnel plots.
Data synthesis
Quantitative analyses
We summarised data statistically if they were available, sufficiently
similar and of sufficient quality. We performed statistical analyses
according to the statistical guidelines referenced in the newest ver-
sion of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2009).
Meta-analyses were conducted using a random-effectsmodel . The
results of each RCT were plotted as point estimates with corre-
sponding 95% confidence intervals. Statistical heterogeneity was
tested using the Z score and the Chi2 statistic with significance
being set at P < 0.10. Quantification of the effect of heterogeneity
was assessed by means of I2, ranging from 0% to 100% includ-
ing its 95% confidence interval (Higgins 2009). The I2 statistic
demonstrates the percentage of total variation across studies due to
heterogeneity and was used to judge the consistency of evidence.
If the evidence of statistical heterogeneity would be substantial (I2
greater than 50%), the potential sources of variation between the
RCTs would be investigated using subgroup analyses.
Qualitative analyses (best-evidence synthesis)
When severe clinical or statistical heterogeneity was found, a qual-
itative analysis (best-evidence synthesis) was performed to summa-
rize the results of the included studies in terms of strength of the
scientific evidence. Findings were considered consistent if more
than one of the studies reported the same direction of the effect
on the outcome measure.
Subgroup analysis and investigation of heterogeneity
If the data permitted, we planned to perform subgroup analyses to
determine whether there were any systematic differences between
groups of patients. We mainly carried out subgroup analyses if
one of the primary outcome parameters demonstrated statistically
significant differences between intervention groups. In any other
case subgroup analyses were planned to be clearly marked as a
hypothesis generating exercise.
A priori defined subgroup analyses were:
• HbA1c level at baseline (subdividing into three groups of
low (less than 7.0%), medium (between 7.0% and 11.0%) and
high level (11.0% or higher) - based on data);
• diabetes duration (up to one year past diagnosis vs duration
over one year);
• duration of intervention (short-term (up to six months
follow-up), medium-term (between 6 and 12 months follow-
up), long term (12 months follow-up or more)).
• age groups (below 60 years, over 60 years);
• gender;
• presence of complications (e.g. diabetic complications);
• different comparison interventions;
• type of treatment: oral hypoglycaemic agents, diet, exercise,
no treatment;
• weight (normal (body mass index - BMI: women less than
25, men less than 27), overweight (BMI: women 25 to 30, men
27 to 30) obese (BMI more than 30)).
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect size:
• repeating the analysis excluding unpublished studies;
• repeating the analysis taking account of risk of bias:
• repeating the analysis excluding very long or large studies to
establish how much they dominate the results;
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
We also planned to test the robustness of the results by repeating
the analysis using different measures of effect size (relative risk,
odds ratio etc.) and different statistical models (fixed-effect model
and random-effects model).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The electronic database search identified a total of 1138 citations
(Figure 1). After excluding titles and abstracts clearly not related
to the objective of our review, 36 full text publications were re-
trieved for further examination. Screening of references resulted in
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another 15 citations. One trial (DiGEM trial 2007) had multiple
publicationswhich displayed the design of the trial (Farmer 2005),
set out different outcome measures (Farmer 2007; French 2008;
Simon 2008) and one overall publication (Farmer 2009). One
retrieved publication of Siebolds et al (Siebolds 2006) described
additional results of the trial of Schwedes et al (Schwedes 2002), a
trial thatwas included in the original review.Results from that pub-
lication were used to supplement the trial of Schwedes et al, now
referred to as SMBG study group 2002. The search identified one
letter to the editor and four abstracts submitted to international
conferences all describing a randomised controlled trial. Three of
the abstracts had already been published and identified as an eligi-
ble trial (Davidson 2004; Drouin 2002; O’Kane 2006). Detailed
trial information on the letter to the editor (Shiraiwa 2010) and
the fourth abstract (Atsumi 1997) could not be retrieved and were
therefore excluded (Atsumi 1997). One trial stopped following
the control group after three months (Chidum 2011). We unsuc-
cessfully requested additional data on the control group from the
corresponding author. Therefore, we excluded this study as well
(Chidum 2011).
Searching the database of ongoing trials identified five registered
trials related to our objective. Two trials were completed and had
already been published and identified as an eligible trial (DiGEM
trial 2007; O’Kane 2008) and three trials were still ongoing (
Bergenstal 2005; Malanda 2009; Kleefstra 2010). The authors
of these trials were contacted and asked to provide (published or
unpublished) data for the review. Only one author provided the
requested data (Kleefstra 2010).
Finally, six eligible RCTs met all inclusion criteria and were added
to the six trials included in our previous review. In total, 12 trials
were included in this review.
We asked the corresponding authors of the DiGEM trial 2007,
Durán 2010, Kleefstra 2010 and O’Kane 2008 to provide short-
term follow-up data if available. They were asked if they could cal-
culate changes in HbA1c for short-term follow-up and to provide
this in terms of means (SD). All authors responded and provided
the additional data as requested.
Included studies
See: Characteristics of included studies andTable 1 for an overview
of study populations and Appendix 2 for baseline characteristics
of included studies.
Nine trials compared self monitoring of blood glucose (SMBG)
with usual care without monitoring (Barnett 2008; Davidson
2005;Durán 2010; Franciosi 2011;Guerci 2003; Kleefstra 2010;
Muchmore 1994; O’Kane 2008; SMBG study group 2002), one
study compared SMBG with self-monitoring of urine glucose
(SMUG) (Allen 1990), one study was a three-armed trial com-
paring SMBG and SMUGwith usual care (Fontbonne 1989) and
one study was a three-armed trial comparing less intensive SMBG,
and more intensive SMBG with a control group (DiGEM trial
2007). Three of these 12 trials had a multi-centred design with
centres in two (SMBG study group 2002), three (Franciosi 2011),
and seven (Barnett 2008) countries, respectively. Trial duration
ranged from 26 weeks to 12 months. The majority of the trials
(seven trials) included over 100 patients in the studies (range 195
to 689). All trials investigated effects of SMBG in patients with a
diabetes duration of at least one year, except for O’Kane 2008 and
Durán 2010. These two trials studied SMBG effects in newly di-
agnosed patients exclusively. Specifications on type, doses or com-
binations of prescribed oral treatments were provided by Barnett
2008,DiGEM trial 2007,Durán 2010, Franciosi 2011,Davidson
2005, Kleefstra 2010 and O’Kane 2008, however details differed
per trial. Furthermore, investigated SMBG interventions differed
in accompanying education programmes (Appendix 3).
Excluded studies
Studies were excluded from the review because they had a con-
trol group with access to SMBG (i.e. Polonsky 2011), they had
included patients using insulin (i.e. Lim 2011), they did not ex-
plored one of our primary outcome measures (i.e. Scherbaum
2008), were secondary reports of studies all ready included (i.e.
Pignone 2009) or because patients were not randomised (i.e.
Bajkowska-Fiedziukiewicz 2008).
Risk of bias in included studies
See Figure 2 and Figure 3 for a graphical summary of the ’Risk
of bias’ assessments for included studies, based on the six ’Risk of
bias’ domains.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Overall risk of bias
Initial agreement between both review authors on the ’Risk of
bias’ domain allocation concealment was 0.56 (kappa). Disagree-
ment was mainly based on reading errors and differences in in-
terpretation of the standard description described in the Cochrane
Handbook for Systematic Reviews of Intervention. After the consen-
sus meeting, no disagreement persisted. The third review author
was not called to make a final decision.
Allocation
Five trials had adequate concealment of allocation ( Barnett 2008;
DiGEM trial 2007; Franciosi 2011; Kleefstra2010;O’Kane2008)
and five trials were unclear about allocation concealment (Allen
1990; Davidson 2005; Durán 2010; Fontbonne 1989; ; SMBG
study group 2002;). In the trial of Guerci et al (Guerci 2003) pa-
tients were randomised by their general practitioners who were
also responsible for intervention and follow-up, and Muchmore
et al (Muchmore 1994) recruited patients were divided over four
groups, of which one group was not randomised. Therefore,
Muchmore 1994 and Guerci 2003 had a high risk of bias for con-
cealment of allocation.
Adequate sequence generation showed a low risk of bias in six
trials (Allen 1990; Barnett 2008; DiGEM trial 2007; Franciosi
2011; Kleefstra 2010; O’Kane 2008), an unclear risk of bias in
five trials (Davidson 2005; Durán 2010; Fontbonne 1989; Guerci
2003; SMBG study group 2002) and was not described in one
(Muchmore 1994). The DiGEM trial 2007 used a computerised
partial minimisation procedure for sequence generation; in the
Allen 1990 et al trial sequence was computer generated. Barnett
2008 used a non-defined random sequence, O’Kane 2008 used
randomly generated codes for consecutively numbered sealed en-
velopes, Kleefstra 2010 had consecutively numbered non-trans-
parent envelopes (range 1 to 60) and Franciosi 2011 used com-
puter-generated randomisation tables (random permuted blocks).
Blinding
In none of the studies patients were blinded to the intervention.
The care provider was only blinded in the trial of Davidson et al
(Davidson 2005). In that trial the care provider was a study nurse
who was kept blinded for the allocated intervention and followed
detailed algorithms to make therapeutic decisions, regardless of
randomisation group.
The primary outcome (HbA1c) was assessed independently of staff
responsible for performing analyses in three trials (DiGEM trial
2007; Kleefstra 2010; O’Kane 2008). Additionaly, treatment al-
location was concealed for laboratory staff. Blinding of the out-
come assessor was not done in Franciosi 2011 and unclear or not
described in the other trials.
Incomplete outcome data
Eight trials described drop-out rates and provided reasons for it
(Allen 1990; Barnett 2008; Davidson 2005; DiGEM trial 2007;
Durán 2010; Franciosi 2011; Kleefstra 2010; O’Kane 2008).
Therefore, in these eight trials we assessed risk of bias concerning
drop-out rate as low. Drop-out was not clearly described in the
SMBG study group 2002 trial.
Intention-to-treat analysis was performed in five trials (Davidson
2005; DiGEM trial 2007; Durán 2010; Kleefstra 2010; O’Kane
2008), which we defined as having a low risk of bias. Five trials
performed per-protocol analyses only and were considered having
a high risk of bias (Allen 1990; Barnett 2008; Fontbonne 1989;
Guerci 2003; SMBG study group 2002) and one trial did not de-
scribe performing either intention-to-treat or per-protocol analy-
ses (Muchmore 1994).
Selective reporting
Three trials (DiGEM trial 2007; Kleefstra 2010; O’Kane 2008)
had a low risk of selective reporting bias by either publishing their
design (DiGEM trial 2007), by registering their protocol in a trial
register (DiGEM trial 2007; Kleefstra 2010; O’Kane 2008) or
both.We ratedDurán 2010 and Franciosi 2011 as unclear because
they both registered their protocol to a trial register three years
after the start of the trial. In addition, Durán 2010 used a hard
to interpret primary outcome measure. The rest of the included
studies were rated as unclear as no information on pre-designated
endpoints or a-priori defined subgroup analysis was identified.
Other potential sources of bias
All trials had similar groups at baseline for the most important
prognostic indicators, except for Kleefstra 2010. In that study,
diabetes duration differed between the intervention and control
group. With the exception of SMBG study group 2002, co-in-
terventions were similar or avoided in all studies. We evaluated
that the SMBG group in SMBG study group 2002 received a co-
intervention by means of a structured counselling program every
four weeks during the intervention period while the control group
only received non-standardised counselling.
See: Appendix 3 for an overview of education programmes for
included studies.
Effects of interventions
See: Summary of findings for the main comparison Self-
monitoring of blood glucose in patients with type 2 diabetes
mellitus who are not using insulin
See Appendix 4 for the effects of SMBG on glycosylated haemo-
globin A1c (HbA1c) and fasting plasma glucose (FPG), Appendix
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5 for the effects of SMBG on health-related quality of life, well-
being and patient satisfaction and Appendix 6 for adverse events
(e.g. hypoglycaemic episodes).
Heterogeneity
Included studies differed in baseline characteristics and in deliv-
ered SMBG education. Due to clinical heterogeneity we decided
not to conduct a pooled analysis of all trials. We performed ran-
dom-effects subgroup meta-analyses on the basis of diabetes du-
ration and follow-up.
Primary outcomes
Glycaemic control measured by HbA1c
Glycaemic control as measured by change inHbA1c between base-
line and endpoint improved in the SMBGgroups (Davidson 2005;
DiGEM trial 2007; Kleefstra 2010; Muchmore 1994; O’Kane
2008), however this was not statistically significantly different
from the improvement seen in the control groups. In their study
Fontbonne 1989 compared control with SMBG and SMUG and
found no statistically significant differences in HbA1c between
groups at the end of the trial. Allen 1990 compared SMBG with
SMUG and found no statistically significant differences in HbA1c
between groups at the end of the study. Five studies detected a sta-
tistically significant difference between the outcomes of the inter-
vention and control groups: The SMBG study group 2002 found
an improvement in glycaemic control in the SMBG group com-
pared to the control group, asmeasured by a statistically significant
difference of 0.5%HbA1c between baseline and endpoint; Guerci
2003 found a statistically significant difference of 0.4% in HbA1c
between SMBG and control group at the end of the study; Barnett
2008 reported an improvement in glycaemic control as measured
with a statistically significant between group difference of 0.2%
HbA1c in favour of the SMBG group; Durán 2010 reported a sta-
tistically significant difference of 0.5% in HbA1c between SMBG
and control group at the end of the study; Franciosi 2011 found
a statistically significant improvement of 0.5% in HbA1c in the
SMBG group compared to the control group between baseline
and endpoint.
Subgroup analyses
We performed subgroup analyses for diabetes duration and du-
ration of the intervention for the comparison of SMBG versus
control and SMBG versus SMUG. Data available on age groups,
gender, presence of complications, different comparison interven-
tions, type of treatment and weight could not be extracted suffi-
ciently or could not be delivered by the original authors to inves-
tigate subgroup. In addition, we decided not to investigate base-
line glycaemic control because 10 out of 12 studies (Allen 1990;
Barnett 2008; Davidson 2005; DiGEM trial 2007; Fontbonne
1989; Franciosi 2011;Guerci 2003; Kleefstra2010;O’Kane 2008;
SMBG study group 2002) were in the a-priori specified medium
range (between 7.0% and 11.0% HbA1c). The remaining two
studies (Durán 2010; Muchmore 1994) had a baseline HbA1c in
the low and the high category, respectively.
For all comparisons, six months follow-up data (published or re-
trieved by contacting the authors) or 12 months follow-up data
were used only:
SMBG vs control (diabetes duration greater than one year,
six months follow-up)
In the meta-analysis, the overall effect for short-term follow-up
(up to six months of follow-up) showed a statistically significant
decrease of 0.3% in HbA1c (95% CI -0.4 to -0.1; 2324 partici-
pants, 9 trials, Analysis 1.1) in favour of SMBG compared with
the control group. For this analysis mild statistical heterogeneity
was noticed (I2 = 29%) (Figure 4).
Figure 4. Forest plot of comparison: 1 SMBG (self-monitoring of blood glucose) vs control (6 months follow-
up), outcome: 1.1 HbA1c [%].
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SMBG vs control (diabetes duration greater than one year,
12 months follow-up)
For medium term follow-up (between 6 and 12 months of fol-
low-up) analysis revealed a statistically non-significant decrease in
HbA1c of 0.1% (95% CI -0.3 to 0.04; 493 participants, 2 trials,
Analysis 2.1) and no statistical heterogeneity (I2 = 0%) (Figure 5).
Figure 5. Forest plot of comparison: 2 SMBG (self-monitoring of blood glucose) vs control (12 months
follow-up), outcome: 2.1 HbA1c [%].
SMBG vs control (newly diagnosed diabetes, six months fol-
low-up)
The pooled analysis for short-term follow-up (up to six months of
follow-up) in newly diagnosed patients (345 participants, 2 trials)
showed notable statistical heterogeneity (I2 = 68%), indicating a
substantial inconsistency in the direction of effect. Therefore, we
do not present an effect estimate for HbA1c for this analysis.
SMBG vs control (newly diagnosed diabetes, 12 months fol-
low-up)
The meta-analysis for medium-term follow-up (between 6 and
12 months of follow-up) in newly diagnosed patients revealed a
statistically significant decrease in HbA1c of 0.5% (95% CI -0.9
to -0.1; 345 participants, 2 trials, Analysis 4.1) accompanied by
moderate statistical heterogeneity (I2 = 44%) (Figure 6).
Figure 6. Forest plot of comparison: 4 SMBG (self-monitoring of blood glucose) vs control (newly diagnosed
patients, 12 months follow-up), outcome: 4.1 HbA1c [%].
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SMBG vs SMUG (diabetes duration greater than one year, six
months follow-up)
The pooled comparison between SMBG and SMUG for a short-
term follow-up (up to six months of follow-up) showed a statis-
tical non-significant decrease in HbA1c of 0.2% (95% CI -1.0 to
0.6; 194 participants, 2 trials, Analysis 5.1) in HbA1c . Statistical
heterogeneity was not observed (I2 = 0%).
Sensitivity analyses
Not enough adequate data to performmeaningful sensitivity anal-
yses.
Quality of life, well-being and patient satisfaction
A total of five trials reported outcomes on either patient satisfaction
(DiGEM trial 2007; Kleefstra 2010; O’Kane 2008; SMBG study
group 2002), well-being (DiGEM trial 2007; Kleefstra 2010;
O’Kane 2008; SMBG study group 2002) and/or health-related
quality of life (DiGEM trial 2007; Kleefstra 2010; Muchmore
1994).
Because of the fragmentation in used (validated) instruments
and underlying sub-dimensions formeasuring patient satisfaction,
well-being and quality of life, risk of bias regarding differences
between studies should be taken into account. A detailed specifi-
cation of used measures can be found in Appendix 5.
None of the trials reporting outcomes on treatment satisfaction
(DTSQ) found significant between group changes (DiGEM trial
2007; Kleefstra 2010; O’Kane 2008; SMBG study group 2002;
). Well-being was assessed with the Well-being Questionnaire in
SMBG study group 2002,O’Kane 2008 and DiGEM trial 2007,
and with the Wellbeing Index in Kleefstra 2010. SMBG study
group 2002 reported a statistically significant decrease of the 22-
itemWell Being Questionnaire (WBQ-22) sub scale depression in
favour of the SMBG group (-0.83 vs -0.26; range 0 to 18). O’Kane
2008 reported a 6% increase (1.08 points) in the depression sub
scale of the WBQ-22 (range 0 to 18) in the SMBG group com-
pared to the control group at 12 months (P = 0.01). Information
on baseline differences was not presented. Both studies did not
find statistically significant differences on general well-being or the
other three well-being sub-scales (anxiety, energy, positive well-be-
ing). The DiGEM trial 2007 found no between group differences
in well-being scores (12-item Well Being Questionnaire (WBQ-
12)). Kleefstra 2010 found no significant changes between groups
in psychological well-being measured with the 5-item Wellbeing
Index (WHO-5). Outcomes on health-related quality of life were
reported by Muchmore 1994, DiGEM trial 2007 and Kleefstra
2010. Muchmore 1994 found no significant differences between
the SMBG group and the control group in the four sub-scales (sat-
isfaction, impact, diabetes related worry, and the social/vocational
worry) of the Diabetes Quality-of-Life Inventory. The DiGEM
trial 2007 found that health-related quality of life as measured
with the EuroQol 5 dimensions (EQ5D) questionnaire showed
a statistically significant difference of -0.1, (95% CI -0.127 to -
0.017; range 1 to 3) at the end of the trial when comparing the
more intensivemonitoring groupwith the control group. Kleefstra
2010found no significant changes between groups in health re-
lated quality of life (36-item Short Form Health Survey (SF-36)).
Separate analyses of the SF-36 sub scales identified a statistical sig-
nificant between groups difference in the sub scale health change
at the end of the study in favour of the control group (a 4.2 points
decrease in the SMBG group and a 9.7 points increase in the con-
trol group; range 0 to 100).
Secondary outcomes
Glycaemic control measured by fasting plasma glucose
Allen 1990, Guerci 2003 and Barnett 2008 measured fasting
plasma glucose levels. All three studies found that fasting plasma
glucose levels decreased as a result of SMBG, however there were
no statistically significant differences between SMBG and SMUG
and SMBG and no monitoring.
Adverse effects, hypoglycaemic episodes
Guerci 2003, DiGEM trial 2007, Barnett 2008, O’Kane 2008,
Durán 2010 and Franciosi 2011 investigated SMBG related hy-
poglycaemia. Studies reported occurrence of hypoglycaemia by
recording asymptomatic or symptomatic hypoglycaemic episodes
and/or by using detailed graded definitions. Because of the frag-
mentation in definitions of hypoglycaemia, risk of bias regarding
occurrence and severity of hypoglycaemia between studies should
be taken into account. A specification of definitions and cut-
off points can be found in Appendix 6. In Guerci 2003 10.4%
SMBG group and 5.2% control group patients reported at least
one episode of symptomatic or asymptomatic hypoglycaemia dur-
ing the study (P = 0.003). This significant difference was caused
by a between-group difference in patients reporting asymptomatic
hypoglycaemia only (P = 0.001). No patients reported serious
episodes of hypoglycaemia. In the DiGEM trial 2007 episodes
of hypoglycaemia with mild symptoms were reported by 9.2%,
22% and 28.5% of the patients in the control group, less inten-
sive group and more intensive group, respectively (P < 0.001).
Episodes of severe hypoglycaemia were reported in one patient in
the control group (DiGEM trial 2007). In the Barnett 2008 study
a hypoglycaemic event (symptomatic, asymptomatic or SMBG
confirmed) was reported in 8.7% and 7% of the patients in the
SMBG group and control group, respectively. All reported events
were considered mild (grade 1), moderate (grade 2) or were non-
graded. No significant between-group differences were found in
reported hypoglycaemia at any time point in the O’Kane 2008
trial. In the Durán 2010 trial no severe hypoglycaemic episodes
requiring third-party or medical assistance were reported in either
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group. In the Franciosi 2011 trial no adverse events including hy-
poglycaemic events occurred.
Barnett 2008 and Guerci 2003 reported adverse effects, but did
not specify them. For details on adverse effects see Appendix 6.
Costs
Allen 1990 and the DiGEM trial 2007 reported outcomes on
approximate costs of self-monitoring. Allen 1990 compared the
costs of SMBG with SMUG based on nine measurements per
week andwith the prices inUS dollars for self-monitoring in 1990.
They concluded that total costs in the first year of SMBG, with
the purchase of a reflectance meter were 12 times more expensive
thanSMUG(SMBG=$481or 361EURO[11/2011 conversion];
SMUG = $40 or 30 EURO [11/2011 conversion]).
As part of the DiGEM trial 2007 a full economical evaluation
of the costs and effects of self-monitoring in the DiGEM trial
population was performed and presented in UK Pounds Sterling.
At the end of the trial, costs for the intervention were £89 (104
EURO [11/2011 conversion]) for standardized usual care (con-
trol group), £181 (212 EURO [11/2011 conversion]) for the less
intensive self-monitoring group and £173 (203 EURO [11/2011
conversion]) for the more intensive self-monitoring group.Higher
losses to follow-up in the more intensive self-monitoring group
were responsible for the difference in costs, compared to the less
intensive self-monitoring group.
Morbidity, mortality
TheDiGEMtrial 2007 andGuerci 2003 reportedmortality (death
of patients during the trial). None of the studies reported data on
morbidity. We have summarised the data in Appendix 6.
D I S C U S S I O N
Summary of main results
The aim of this systematic reviewwas to assess the effects of SMBG
in patients with type 2 diabetes who are not using insulin. Six
randomised controlled trials were added to the six trials included
in the original review (Welschen 2005a). In non-insulin treated
type 2 diabetes patients with a diabetes duration of at least one
year the overall effect of SMBG compared to control groups and
a follow-up of six months showed a statistically significant 0.3%
HbA1c decrease. In contrast, we saw a non-significant decrease of
0.1% in HbA1c in patients in SMBG groups compared to control
groups over a 12 months follow-up period.
Secondly, the overall effect of SMBG compared to SMUG over
a follow-up of six months showed a statistically non-significant
decrease of 0.2% HbA1c . Thirdly, it was not possible to estimate
an overall effect of SMBG over a follow-up of six months for
newly diagnosed non-insulin treated type 2 diabetes patients, due
to substantial inconsistency in the direction of the effect. How-
ever, the overall effect of SMBG with a follow-up of 12 months
demonstrated a statistically significant decrease of 0.5% in HbA1c
compared to control groups (two trials).
Concerning health-related quality of life, well-being and patient
satisfaction outcomes, based on a best-evidence synthesis we con-
clude that there was no significant evidence available that SMBG
had an effect on patient satisfaction (4 out of 4 trials), general
well-being (4 out of 4 trials) or general health-related quality of
life (3 out of 3 trials). Regarding levels of depression (WBQ-22,
sub scale), inconsistent findings were observed (2 out of 2 trials).
Lastly, regarding the secondary outcomes we conclude that based
on a best-evidence synthesis periods of both asymptomatic and
symptomatic hypoglycaemia are more frequent in patients per-
forming SMBG (3 out of 4 trials); and secondly, there is no sta-
tistically significant difference in fasting plasma glucose levels be-
tween SMBG and control intervention groups (3 out of 3 trials).
Clinical relevance of findings
The main results suggest that long-term SMBG in new-onset pa-
tients is beneficial in lowering HbA1c . However, when diabetes
duration is over one year, the overall glycaemic effect of SMBG
is small and more likely to be present at short-term. Because sub-
group meta-analyses could not fully take the presence of clinical
heterogeneity into account, clinical interpretation and translation
into practice of these results is difficult and should be done with
caution. Different levels of probability and estimates of outcome
variables of included studies might account for differences in pre-
sented subgroups. In addition, differences in requested monitor-
ing frequency, HbA1c level at baseline and SMBG and diabetes
education may have contributed to the differences as well. Besides
HbA1c we paid attention to important outcome measures such as
health-related quality of life, well-being, patient-satisfaction and
hypoglycaemic episodes as well. Because few included trials re-
ported outcomes on health-related quality of life and well-being
and used self-report measures varied, presenting a general effect
estimate is not possible and interpretation of best-evidence syn-
thesis is difficult. However, similar effects on similar sub-scales or
dimensions in similar directions suggested a clinical non-relevant
effect of SMBG on general (health-related) quality of life and well-
being. In addition, since all trials that measured patient-satisfac-
tion did not report an SMBG related effect, this is considered clin-
ical relevant as well. Experiencing hypoglycaemic events can be
confirmed with SMBG. Therefore, it is in the line of expectation
that more frequent hypoglycaemic events are reported when using
SMBG.
Overall completeness and applicability of
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evidence
Risk of bias
Most included trials and specifically earlier trials were exposed
to selection and attrition bias . With the advent of new studies
(Barnett 2008; DiGEM trial 2007; Durán 2010; Franciosi 2011;
Kleefstra 2010; O’Kane 2008) performed after our first review
(Welschen 2005a) the risk of bias was reduced.
Primary outcome
SMBG was embedded differently in usual care across included
trials and instructions for self-monitoring frequency, ’lifestyle’ ad-
justment and SMBG integration in diabetes management varied
between trials. However, we considered clinical heterogeneity in-
duced by trial design not significant and decided to combine the
data in subgroup meta-analyses.
We made an a-priori decision to separate pooled estimates of the
effect of SMBG on HbA1c for newly diagnosed patients and pa-
tients with a diabetes diagnosis of at least one year. Initiating dia-
betes management in newly diagnosed and never treated patients
results in larger and differential effects in glycaemic control com-
pared to patients with a longer diabetes duration (Schwedes 2002).
In addition, being confronted with having a major chronic disease
as type 2 diabetes can be accompanied with newly gained worries,
which directly reflects in glycaemic control (Schwedes 2002).
Secondary outcomes
In none of the trials, psychological measures were the primary
outcome measures. Some trials mentioned contradictory or no
psychological effects as secondary outcome measures. Finally, hy-
poglycaemic episodes were more reported in SMBG groups than
in the control groups (Barnett 2008; DiGEM trial 2007; Guerci
2003; O’Kane 2008). Because patients in the SMBG groups can
use their SMBG device to confirm both periods of asymptomatic
and symptomatic hypoglycaemic, this is according to expectations.
Quality of the evidence
This update identified six new studies. Inclusion of these new stud-
ies made it possible to perform subgroup meta-analyses on dura-
tion of diabetes and duration of intervention. Initially, subgroup
analyses of studies with a short intervention duration (9 studies,
2324 participants) showed a larger positive effect of self-moni-
toring compared to studies with a medium duration (2 studies,
493 participants). Effects of short- and medium-term duration
in patients with newly diagnosed type 2 diabetes (2 studies, 345
participants) were subject to notable (I2 = 68%) and moderate (I2
= 44%) statistical heterogeneity, respectively. Therefore, no sum-
mary estimate can be presented for short-term follow-up and long-
term follow-up should be interpreted with caution. Concerning
the studies evaluating the effect of SMBG compared with SMUG
the results of the current review are insufficient to draw final con-
clusions. Only two studies with 194 participants were identified
and included in the analysis. Pooling the data from these two stud-
ies showed a non-significant positive effect of SMBG on HbA1c
compared to SMUG.However, one of the trials (Fontbonne 1989)
had serious limitations in design and implementation, which may
have resulted in selection, attrition and reporting bias.
Potential biases in the review process
With an extensive search without language restriction in four elec-
tronic databases, the meta-register of current controlled trials and
by scanning references of identified reviews and included studies
we attempted to minimise publication bias. Nevertheless, we can-
not rule out the possibility thatwe havemissed relevant studies that
were not published or are still ongoing. Not all data needed to per-
form a full effect-modifier investigation could be extracted from
the data available or revealed from the original authors. There-
fore, differences in baseline glycaemic control, changes in hypo-
glycaemic medication, age and compliance to the protocol might
modify or confound the presented results. In addition, the pro-
posed sensitivity analyses could not be performed.
Agreements and disagreements with other
studies or reviews
The efficacy of SMBG in type 2 diabetes patients not using in-
sulin has been subject of a considerable number of systematic re-
views and meta-analyses over time. Most included randomised
controlled trials only (Allemann 2009; Clar 2010; Jansen 2006;
Kleefstra 2009; McIntosh 2010; Poolsup 2008; Poolsup 2009;
Sarol 2005; Towfigh 2008), but some included other designs as
well (McAndrew 2007; McGeoch 2007; St John 2010). The aim
of our review was to assess the effects of SMBG in type 2 dia-
betes patients not using insulin. Therefore, studies in which the
results of non-insulin users could not be separated from patients
using insulin were excluded. Although this stringent exclusion cri-
terion contributes to a decrease in included patients we believe
that this has lead to a more clinically homogeneous data set and
more valid conclusions about the effect of SMBG in this particu-
lar patient group. Furthermore, in contrast to other reviews, clin-
ical and methodological heterogeneity between included studies
have been taken into account. We believe that this distinguishes
our systematic review and its associated conclusions from previous
ones and emphasises the importance of comparability and internal
validity of RCTs.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
In this update, the addition of six new trials to the original review
made it possible to create subgroups to counter the initial lack of
clinical and methodological homogeneity between studies. With
the present findings it can be concluded that self-monitoring of
blood glucose (SMBG) in newly diagnosed type 2 diabetes pa-
tients who are not using insulin is beneficial in lowering HbA1c .
However, when diabetes duration is over one year, the overall gly-
caemic effects of SMBG are small at short-term and subside af-
ter one year. Despite possible glycaemic benefits we conclude that
SMBG has no relevant effect on general well-being and health-
related quality of life. In addition, patients performing SMBG are
equally satisfied with their treatment as those not using SMBG.
Furthermore, SMBG increases reported hypoglycaemic episodes.
However, different definitions of hypoglycaemic episodes make it
difficult to distinguish between reported severities.
Implications for research
Qualitative research (Farmer 2009; Peel 2007) suggests that
SMBG and its feedback can be important factors for individual
patients to improvemedication adherence, empower the patient to
gain control over their disease or tomotivate ’lifestyle’ changes. Fu-
ture studies should investigate whether SMBG attributes to other
parts of self-management. In addition, SMBG postulated positive
changes in diabetic complications should be investigated as well.
Furthermore, more research is needed to explore the psychologi-
cal impact of SMBG and its accompanying demands on diabetes
specific quality of life and well-being.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 1990
Methods Randomised controlled trial. Randomised in groups of 10 with the use of a computer-
generated table of random numbers
Participants Country: USA
Number of participants: 54
Inclusion criteria:
• type 2 diabetes, not treated with insulin;
• fasting plasma glucose level > 8.8 and <22 mM;
• no history of ketoacidosis;
• current treatment with diet alone or diet and an oral hypoglycaemic agent;
• no active infection or serious illness;
• no physical or mental handicap precluding participation in the treatment
program (determined by the Cognitive-capacity screening examination and a physical-
abilities questionnaire).
Exclusion criteria:
• SMBG devices used previously;
• serum creatinine level > 177 mM.
Mean age (years ± SD):
• SMBG: 58.2 ± 9.7
• SMUG: 57.9 ± 10.7
Diabetes duration (years ± SD):
• SMBG: 6.8 ± 6.5
• SMUG: 9.0 ± 10.3
Interventions 1. SMBG group (n = 27) and standardized treatment program including diet and
exercise counselling. At least 36 blood glucose determinations/month, before each meal
every other day.
2. SMUG group (n = 27) and standardized treatment program including diet and
exercise counselling. At least 36 urine glucose determinations/month, before each meal
every other day.
Outcomes 1. Fasting plasma glucose, obtained monthly by glucose oxidase method.
2. Glycosylated haemoglobin, obtained initially and at 3 and 6 months by affinity
chromatography.
3. Total cholesterol and high-density lipoprotein cholesterol, measured by
spectrophotometer with Beckman Dri-STAT reagents.
4. Weight, obtained monthly, patients fully clothed.
5. Respective costs of the two monitoring techniques.
Study details Duration: 6 months
Publication details Language of publication: English
Funding: the Veterans Administration Health Services Research and Development Ser-
vice and additional funds from the A.W. Mellon Foundation
Publication status: Peer reviewed journal
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Allen 1990 (Continued)
Stated aim of study ”To compare the relative efficacy and cost of self-monitoring of blood glucose with
routine urine testing as part of a standardized treatment programme in the management
of patients with type 2 non insulin dependent diabetes, not treated with insulin“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomised in
groups of 10...... with the use of a com-
puter-generated table of random numbers“
Allocation concealment (selection bias) Unclear risk Comment: No information is available
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Quote: ” Blinding of the patients or study
physician to the interventions, either urine
or blood testing, was not possible“
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Quote: ” Blinding of the patients or study
physician to the interventions, either urine
or blood testing, was not possible“
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: No information is available
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote: ”Five patients were inappropriately
randomised and participated for less than
one week“. Quote: After 2 months of par-
ticipation, 2 patients dropped out for un-
known reasons”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
High risk Quote: “Of the 61 patients randomised to
the competing interventions, 54 completed
the study”. Comment: Only 54 out of 61
patients were included in the analysis
Selective reporting (reporting bias) Unclear risk Comment: No trial registration or protocol
available
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “The two groups were similar in all
baseline measurements”
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Allen 1990 (Continued)
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment: All patients received the same
diet instructions and were individually in-
structed in testing techniques
Quote: “Physician-initiated treatment al-
terations were guided by an explicit algo-
rithmwith the patients’s urine or blood test
results and the monthly fasting glucose val-
ues”
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “Compliane levels were similar for
both groups of patients”
Comment: 87% SMUG and 90% SMBG
of patient records were complete and atten-
dance exceeded 98% in both groups
Barnett 2008
Methods Multicentre randomised parallel-group trial
Participants Countries: Czech Republic, Hungary, Iran, Malaysia, Poland, Slovakia, Turkey
Number of participants: 610
Inclusion criteria:
• patients with type 2 diabetes;
• 40 to 80 years of age;
• treatment with diet alone ≥ 3 months, diet and biguanides or alpha-glucosidase
inhibitor or diet plus any inulin secretagogue for < 12 months;
• HbA1c between 7 and 10%.
Exclusion criteria:
• current management with SMBG;
• lifestyle or concurrent condition (medical or psychiatric) that could interfere with
end-point evaluation (serious anaemia, haemoglobinopathy and haemolysis) or ability
to comply with study procedures including SMBG and diary keeping;
• abnormalities on laboratory screening including creatinine clearance < 20 ml/min
and/or serum creatinine > 140 mM and alanine aminotransferase or aspirate
aminotransferase more than 3 times the upper limit of normal range;
• therapy with systemic glucocorticoids;
• known contraindication to gliclazide;
• know drug or alcohol dependence;
• pregnancy, lactation or planned pregnancy.
Mean age (years ± SD):
• SMBG: 56.1 ± 9.1
• Control: 55.9 ± 9.3
Diabetes duration (years ± SD):
• SMBG: 2.8 ± 3.7
• Control: 2.8 ± 4.5
Interventions 1. SMBG (n = 311): measurement of glucose levels 2 days a week (one working and
one non-working day) at 5 times (before each meal (breakfast, lunch, dinner), 2 h after
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Barnett 2008 (Continued)
main meal and before bedtime). Once per month postprandial measurements after
each of the three meals. Instructions in SMBG included information on how to use the
glucose metre, how to check it was working, when to take measurements, how to
record them in a patient diary and what to do in the event of asymptomatic
hypoglycaemia (measured glucose < 3 mmol/L without symptoms suggestive of
hypoglycaemia) or SMBG-confirmed glycaemia.
2. Control (n = 299): all randomised patients received diet and lifestyle advice,
reinforced at each clinic visit. Oral antidiabetic agent therapy (gliclazide MR) was
standard for all patients. Those on insulin secretagogue were transformed to gliclazide
MR. A diary was used to record symptoms of hypoglycaemia, actions taken.
Outcomes Primary outcome:
1. 1 HbA1c between groups at week 27.
Secondary outcomes:
1. Mean changes from baseline HbA1c and FPG at week 27.
2. Gliclazide MR dose.
Study details Duration of intervention: 27 weeks.
Publication details Language of publication: English
Funding: Unristricted grant from Servier
Publication status:Peer reviewed journal
Stated aim of study “First, to evaluate the contribution of SMBG in the management of patients with type
2 diabetes, with an emphasis on glycaemic control. Second, to compare the efficacy,
tolerability and acceptability of an identical once daily gliclazide modified release (MR)
based regimen in patients with type 2 diabetes with and without SMBG”
Notes DYNAMIC-1 study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible patients were randomised
in a sequential manner using a centrally
generated random allocation sequence...”
Allocation concealment (selection bias) Low risk Quote: “....a centrally generated randomal-
location sequence” was used for randomi-
sation
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: patient cannot be blinded to the
intervention
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Barnett 2008 (Continued)
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: care provider cannot be blinded
to the intervention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: Primary outcome was differ-
ence between groups in HbA1c . Though
HbA1c values were measured in a central
national laboratory according to DCCT
standards, un sufficient information on the
HbA1c outcome assessor is given.
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk 610 randomised. SMBG: 37 withdrawals;
Control: 47 withdrawals
Quote: “...271 subjects (87%) in the
SMBG group and 248 (83%) in the non-
SMBG group completed the study”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
High risk Quote: “the primary analysis population
was the full analysis set, defined a priori
in the protocol as all randomised patients
who took at least one dose of gliclazideMR
during the study, who performed SMBG at
least once (SMBG group) and with a base-
line HbA1c and at least one post baseline
HbA1c value”.
Selective reporting (reporting bias) Unclear risk Comment: Insufficient information about
the study protocol is available
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “patient characteristics at study en-
try were similar between the randomisa-
tion groups with the exception of a higher
proportion of menopausal women in the
SMBG group”
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment: Care for both groups is equal.
However, no information is given on a
joint multicenter training on giving diet
and lifestyle advice
Free of other bias?
Was the compliance acceptable in all
groups?
Unclear risk Comment: insufficient information on
compliance is provided
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Davidson 2005
Methods Randomised controlled trial
Participants Country: USA
Number of participants: 89
Inclusion criteria:
• patients not taking insulin.
Mean age (years ± SD):
• SMBG: 49.8 ± 11.2
• Control: 50.9 ± 11.0
Diabetes duration (years ± SD):
• SMBG: 5.5 ± 4.7
• Control: 5.8 ± 5.8
Interventions 1. SMBG (n = 43): measurement of glucose levels before and between one and two
hours after eating meals six days a week.
2. Control (n = 45): patients in both groups were scheduled to meet with dietician
five times; at randomisation and 2, 4, 8 and 12 weeks later. Dietician used glucose
levels and meal descriptions in nutritional counselling. A nurse followed detailed
algorithms to make therapeutic decisions.
Outcomes 1. HbA1c , measured at entry to the study and every two months
Study details Duration: 6 months
Publication details Language of publication: English
Funding:
Publication status: Peer reviewed journal
Stated aim of study ”To answer the important question of whether self monitoring of blood glucose concen-
trations improves HbA1c responses“ through a blinded and randomised study.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: No randomisation method described
Allocation concealment (selection bias) Unclear risk Comment: No treatment allocation described
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: The patient cannot be blinded
Blinding (performance bias and detection
bias)
Low risk Quote: ”the nurse ,who acted as care provider, was un-
aware of whether the patient was randomised to themon-
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Davidson 2005 (Continued)
Was the care provider blinded to the inter-
vention?
itoring group or not...“
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: No detailed information described
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote: ”one patient did not return after being ran-
domised to see the nurse or dietician and was not in-
cluded in the study“
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Quote: ”an intention to treat analysis was used“.
Selective reporting (reporting bias) Unclear risk Comment: No trial record or protocol publication with
pre-designated endpoints is available
Free of other bias?
Where groups similar at baseline?
Low risk Quote: ”There were no differences in the baseline char-
acteristics of the patients randomised to the monitoring
group and those who were randomised to the control
group“
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment: All patients received the same care with the
same detailed algorithm and dietician care
Free of other bias?
Was the compliance acceptable in all
groups?
High risk Quote: ”patients in the monitoring group averaged 4.0
vs 3.2 visits in the control group
Comment: The monitoring group performed an average
number of 129 tests per person instead of the maximum
of 6x6x26=936
DiGEM trial 2007
Methods Three arm, open, parallel group randomised trial
Participants Country: United Kingdom
Number of participants: 453
Inclusion criteria:
• patients with type 2 diabetes;
• 25 years of age or more at diagnosis;
• managed with diet or oral hypoglycaemic agents alone;
• HbA1c level ≥6.2% at the assessment visit;
• independent in activities of daily living.
Exclusion criteria:
• use of blood glucose monitor twice a week or more often over the previous three
months;
• current use of insulin;
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DiGEM trial 2007 (Continued)
• co-morbidity or limited life expectancy that would make intensive glycaemic
control inappropriate;
• inability to follow trial procedures.
Mean age (years ± SD):
• Less intensive SMBG: 65.2 ± 10.6
• More intensive SMBG: 65.6 ± 9.9
• Control: 66.3 ± 10.2
Diabetes duration (median years (q1-q3)):
• Less intensive SMBG: 3 (2-7)
• More intensive SMBG: 3 (2-6)
• Control: 3 (2-6)
Interventions 1. Less intensive SMBG (n = 150): Self testing group performing blood glucose self
testing 2 days a week, 3 tests daily (1 after fasting, 2 before meal or 2 hours after meal)
with instruction to aim for 4-6mmol/Lfasting and 6-8 mmol/L after meals. Results
were interpreted by the study nurse.
2. More intensive SMBG (n = 151): Self monitoring group who, in addition to self
testing group, are provided with training and support in interpreting and applying the
results of blood glucose readings to enhance motivation and maintain adherence to diet
physical activity and medication regimens.
3. Control (n = 152): Standardised usual care and three monthly HbA1c
measurements.
All patients received the use of goal setting and review techniques. A diary was used to
record self care goals and strategies for achieving them
Outcomes Primary outcome:
1. HbA1c level at 12 months
Secondary outcomes:
1. Blood pressure.
2. Weight.
3. Total cholesterol level.
4. Ratio of total cholesterol to high density lipoprotein cholesterol.
5. Body mass index.
6. Well-being (WBQ-12).
7. Self-reported smoking status, dietary intake and physical activity (DSCAQ).
8. Medication adherence (MARS).
9. Patient treatment satisfaction (DTSQ).
10. Beliefs about diabetes and its management (IPQ).
11. Beliefs about medicine (BMQ).
12. Beliefs about physical activity, eating and (using) blood glucose monitoring.
13. Quality adjusted life years (EQ5D).
14. Healthcare costs.
Study details Duration of intervention: 12 months.
Publication details Language of publication: English
Funding: National Health Service and the National Institute for Health Research health
technology assessment programme
Publication status:Peer reviewed journal
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DiGEM trial 2007 (Continued)
Stated aim of study ”To test whether elf monitoring of blood glucose with or without instruction in in-
corporating findings into self care, compared with standardised usual care can improve
glycaemic control in patients with non-insulin treated diabetes“
Notes Diabetes Glycaemic Education Monitoring (DiGEM) trial
Data was extracted from four manuscripts: Farmer 2007, BMJ; French 2008, Diabetic
Medicine; Simon 2008, BMJ; Farmer 2009, Health Technology Assessment.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ” we used computerised randomi-
sation incorporating a partial minimisa-
tion procedure to adjust the randomisation
probabilities between groups...“
Allocation concealment (selection bias) Low risk Quote: ”the minimisation procedure to as-
sign patients to their allocated interven-
tion was conducted independently of the
research nurses who managed recruitment
and carried out assessment visits. The allo-
cation was also concealed from laboratory
staff“
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded to the
intervention
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be
blinded to the intervention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Low risk Quote: ”Treatment allocation was con-
cealed for study nurses and laboratory staff“
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote; ” only 57 patients where lost to fol-
low up (12,6%) which did not differ be-
tween groups“
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Quote: ”we carried out a single intention
to treat analysis of themain trial end points
at the end of the study using ANCOVA
to compare mean levels of HbA1c at fol-
low up between the three allocated groups,
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DiGEM trial 2007 (Continued)
with the baseline level of HbA1c as covari-
ate. If no follow-up data were available we
imputed values by carrying forward the last
available measurement“
Selective reporting (reporting bias) Low risk Comment: All outcomes are pre-specified
available in the published study protocol
Free of other bias?
Where groups similar at baseline?
Low risk Quote: ”Baseline, personal and clinical
characteristics were well balanced between
the groups“
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment: All groups received the same
goal setting and review techniques
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: Ninety nine (67%) in the less in-
tensive group and 52% in the more inten-
sive group continued to use the meter at
least twice a week for the 12 months of the
study”
Durán 2010
Methods a prospective randomised clinic-based interventional study with parallel groups
Participants Country: Spain
Number of participants: 195
Inclusion criteria:
• newly diagnosed type 2 diabetes after two fasting glucose plasma values > 125 mg
dL;
• age 18 to 80 years;
• < 6 months from the first fasting plasma glucose value > 126 mg dL;
• absence of ketones in two first morning urine samples.
Exclusion criteria:
• any fasting glucose levels > 125 mg dL in previous 12 months;
• HbA1c levels > 8% at diagnosis;
• unable to perform SMBG;
• life threatening disease.
Mean age (years ± SD):
• SMBG: 62.5 ± 10.4
• Control: 64.7 ± 9.6
Diabetes duration (years):
• SMBG: 0
• Control: 0
Interventions 1. SMBG based step-by-step treatment (n = 99): lifestyle intervention that used
SMBG as an educational tool to adhere to lifestyle changes, as well as a therapeutic tool
to apply step-by-step pharmacological treatment.
2. HbA1c based step-by-step treatment (n = 62): standard treatment based on
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Durán 2010 (Continued)
HbA1c values without SMBG.
All patients were treated with 850 mg metformin (half a tablet at breakfast, nothing at
lunch and another half tablet at dinner; ½-0-½). Lifestyle interventions were similar for
all patients and were developed after a 2h session for each patient individually and were
reinforced at each follow-up visit
Outcomes Primary outcome:
1. Remission and regression rate of type 2 diabetes.
Secondary outcomes:
changes in
1. HbA1c;
2. fasting insulin;
3. homeostasis model assessment of insulin resistance (HOMA-IR);
4. total cholesterol (high-density lipoprotein (HDL) and low density lipoprotein
(LDL));
5. triglycerides;
6. apolipoprotein B;
7. body weight;
8. waist circumference;
9. blood pressure;
10. adherence to the suggested lifestyle changes.
Study details Duration: 12 months
Publication details Language of publication: English
Funding: Ministerio de Sanidad from Spain (Fondos de Cohesion 2008)
Publication status:Peer reviewed journal
Stated aim of study To investigate the hypothesis that “ in combination with simple algorithms that modify
the doses of glucose-lowering medication, SMBG can prevent acute complications, such
as hypoglycaemia as well as alerting the patient when specialist help and support are
needed”
Notes St. Carlos study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Newly diagnosed T2DM patients
who were eligible for inclusion in the study
were randomly (2:1) assigned to one of two
groups”
Comment: No further information pro-
vided.
Allocation concealment (selection bias) Unclear risk Comment: No information provided
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Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: The patient cannot be blinded
to the intervention
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: The care provider cannot be
blinded to the intervention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: No information stated
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote: “ 29 patients from the supervised
exercise program subgroup of the SMBG
arm were excluded and 5 patients (SMBG
2, control 3) were lost to follow-up”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Comment: Ninety-nine out of 130 ran-
domised patients in the SMBG group were
analysed and 62 in the control group were
analysed
Quote: “a supervised exercise program was
offered to half the patients in the SMBG
group (we expected a 1:1 allocation in these
subgroups) but, surprisingly, only 29 pa-
tients agreed to participate. Given the small
number of SMBG patients in the exercise
programand the possible influence of phys-
ical activity on the three endpoints evalu-
ated, the patients in this subgroup were ex-
cluded from subsequent analysis”
Selective reporting (reporting bias) Unclear risk Comment: Outcomes in the report are
identical to those stated in the recorded
trial register. “Clinical trial number IS-
RCTN81672669 available at http://www.
controlled-
trials.com/ISRCTN81672669”. However,
the trial started in January 2006 but was
registered in 2009. All outcomes are ex-
pressed as median (q1-q3) which indicates
skewness
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “Patient characteristics at the time
of study entry were similar between the two
groups, with the exception of higher LDL
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cholesterol levels in the SMBG compared
with the HbA1c group”.
Free of other bias?
Where co-interventions avoided or similar?
Low risk Quote: “a supervised exercise program was
offered to half the patients in the SMBG
group (we expected a 1:1 allocation in these
subgroups) but, surprisingly, only 29 pa-
tients agreed to participate. Given the small
number of SMBG patients in the exercise
programand the possible influence of phys-
ical activity on the three endpoints evalu-
ated, the patients in this subgroup were ex-
cluded from subsequent analysis”
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “In the SMBG group, 96 of 99 pa-
tients (97%) performed a median of 251
capillary measurements (range 148-300)
during follow-up”. Comment: This is ap-
proximally 1 six point profile per week,
which was recommended
Fontbonne 1989
Methods Randomised controlled trial.
Randomisation procedure stratified by clinic.
Participants Country: France
Number of participants: 208
Inclusion criteria:
• non-insulin dependent diabetes patients;
• treated with diet and/or oral hypoglycaemic agents;
• poorly controlled at entry to trial, FPG > 8.8 mmol/L, or postprandial blood
glucose level > 11.1 mmol/L, 3 times within the preceding year;
• presence of at least occasional glucosuria (renal glucose threshold < 11 mmol/L)
was to be ascertained;
• no rapidly progressing diabetic complications, no severe illness;
• at least 3 years duration of diabetes;
• first contact to the diabetes clinic at least 6 months before entry to trail;
• having attended to at least 2 outpatient visits since their first contact;
Mean age (years ± SD):
• SMBG: 54.5 ± 10.7
• Urine glucose: 54.9 ± 10.2
• Control: 56.3 ± 9.
Diabetes duration (years ± SD):
• SMBG: 12.2 ± 6.6
• Urine glucose: 13.3 ± 6.8
• Control: 12.7 ± 0.8
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Interventions 1. SMUG: self-urine glucose monitoring, twice every other day (n = 54).
2. SMBG: self blood glucose monitoring, twice every other day (n = 56).
3. Control: regular HbA1c determinations every two months, no self-monitoring (n
= 54).
Outcomes 1. Weight, measured every two months.
2. HbA1c assayed by low-pressure liquid chromatography, measured every 2 months.
3. Number of reactive strips reported in a diary, recorded every two months.
Study details Duration: 6 months
Publication details Language of publication: English
Funding: Ames Division, Miles Laboratories.
Publication status:Peer reviewed journal
Stated aim of study ”To determine if the use of self glucose monitoring could help this rather common
type of non insulin-treated diabetic patients (poorly controlled) in achieving improved
metabolic control, by increasing their disease awareness and hence their compliance with
treatment, as well as by giving the physician new evidence on which to adjust diet and
oral treatment“
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”They thenwere randomly assigned
to one of three monitoring groups. The
randomisation procedure was stratified by
clinic.“
Comment: No information on the se-
quence generation available
Allocation concealment (selection bias) Unclear risk Comment: No information on allocation
concealment available
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be
blinded
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Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: No information presented
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
High risk Quote: ”Two-hundred and eight patients
entered the trial...“ ”Forty-four patients
were lost to follow-up, i.e. did not attend
the last visit....“
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
High risk Comment: Differences for outcome crite-
ria between last and first visits are analysed
per protocol
Selective reporting (reporting bias) Unclear risk Comment: No trial register or published
design available
Free of other bias?
Where groups similar at baseline?
Low risk Comment: No differences between groups
were observed.
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment:No specific information ismen-
tioned. However, none of the groups re-
ceived any extra or different advice or treat-
ment
Free of other bias?
Was the compliance acceptable in all
groups?
High risk Quote: ”The number of urine strips used
in the SMUGgroupwas significantly lower
than expected indicating low compliance..
.“ The number of blood strips used was as
expected”
Franciosi 2011
Methods Randomised controlled pilot study
Participants Country: Italy
Number of participants: 62
Inclusion criteria:
• patients with type 2 diabetes;
• age 45 to 75 years;
• HbA1c between 7% and 9% ;
• treated with oral hypoglycaemic agent monotherapy;
• no experience in SMBG in previous 12 months;
• first time in diabetes clinic.
Exclusion criteria:
• incapable of performing SMBG;
• requiring insulin or multiple oral hypoglycaemic agent therapy;
• requirement of regular use of SMBG;
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• diabetes care not exclusive managed by diabetes clinic.
Mean age (years ± SD):
• SMBG: 48.9 ± 0.5
• Control: 48.7 ± 0.6
Diabetes duration (years ± SD):
• SMBG: 3.4 ±3.5
• Control: 3.2 ± 4.4
Interventions 1. Standardized Specific education addressing how to perform SMBG, how to
modify diet and level of physical activity according to blood glucose levels and the
actions to undertake in case of abnormal values.
2. Control group receiving standard counselling with focus on diet and lifestyle.
Outcomes Primary outcome:
1. Change in HbA1c , between groups after 6 months.
Secondary outcomes:
1. Percentage of patients reaching HbA1c target (< 7.0%) .
2. Percentage of patients requiring therapy modifications.
3. Changes in body weight.
4. Changes in lipid profile.
5. Changes in blood pressure values.
Study details Duration: 6 months
Publication details Language of publication: English
Funding: Unconditionally support by LifeScan Inc. Clinical Research Management and
Monitoring
Publication status:Peer reviewed journal
Stated aim of study ”To evaluate the feasibility and efficacy of a self-monitoring disease management strategy
in patients with Type 2 diabetes on oral hypoglycaemic agent therapy“
Notes ROSES-study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Eligible patients were centrally ran-
domised by telephone to intervention group vs.
control group on the basis of random permuted
block computer-generated randomisation tables,
stratified by centre and produced by the coordi-
nating centre.“
Allocation concealment (selection bias) Low risk Quote: ”...patients were centrally randomised by
telephone...“
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Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Quote: “participants, providers and assessors were
not blinded on group/treatment allocation.”
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Quote: “participants, providers and assessors were
not blinded on group/treatment allocation.”
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
High risk Quote: “participants, providers and assessors were
not blinded on group/treatment allocation.”
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote: ”Sixty-two patients were recruited , of
whom five did not complete the follow-up“
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Quote: “all the efficacy analyses were performed
on the intention-to-treat population”
Quote: “all randomised patients were included in
the analyses”
Selective reporting (reporting bias) Low risk Comment: The trial is registered in the Clinical
Trials register but was registered 3 years after study
start date
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “clinical and socio-demographic charac-
teristics compared well between the two groups.
Some variables varied slightly but not signifi-
cantly”
Free of other bias?
Where co-interventions avoided or similar?
Unclear risk Quote: “The control group received standard
counselling with focus on diet and lifestyle”. No
information is provided whether the intervention
group received this also
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “..mean number of SMBG measurements
during the trial was 71 ±11 as compared with the
76 required by protocol.Only 7.1%of the patients
performed less than 80% of the required number
of measurements”
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Methods Randomised controlled trial
Participants Country: France
Number of participants: 689
Inclusion criteria:
• type 2 diabetes with a known duration over 1 year;
• insufficiently controlled with oral antidiabetic treatment (HbA1c > 7.5 and < 11.
0%);
• age between 40 and 75 years;
• not previously treated with insulin;
• not requiring insulin at inclusion;
• not previously received SMBG;
• able to carry out SMBG.
Exclusion criteria:
• type 1 diabetes, MODY and secondary diabetes;
• recent weight loss of more than 3 kg during the last 3 months;
• impending complications of diabetes;
• pregnant women;
• unable to read or write;
• uncooperative.
Mean age (years ± SD):
• SMBG: 60.9 ± 9.4
• Control: 62.2 ± 9.1
Diabetes duration (years ± SD):
• SMBG: 7.7 ± 6.3
• Control: 8.4 ± 6.6
Interventions 1. SMBG (n = 345) in addition to the conventional laboratory work-up. Education
on weight loss and physical activity; treatment alterations by physician. Measurements
at least 6 times per week, on 3 different days, including weekends.
2. Control (n = 344): conventional laboratory work-up based solely on laboratory
measurement of HbA1c every 12 weeks. Education on weight loss and physical activity;
treatment alterations by physician.
Outcomes 1. Weight, systolic and diastolic blood pressure at baseline, 3 and 6 months.
2. HbA1c , determined using the DCA analyser and blood glucose. Measured at
baseline, 3 and 6 months.
3. Number of hypoglycaemic episodes.
Study details Duration: 6 months
Publication details Language of publication: English
Funding:
Publication status:Peer reviewed journal
Stated aim of study ”To compare, over a 6-month period, metabolic control in patients with poorly con-
trolled type 2 diabetes, managed wither with usual recommendations alone (conven-
tional assessment group) or combined with self-monitoring of blood glucose (SMBG
group)“
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Notes ASIA-study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”the patients were randomised to two groups...“.
Comment: No information on randomisation sequence
is available
Allocation concealment (selection bias) High risk Comment: Patients were randomised by their GPs who
also carried out the usual care, dietary advice and the
follow-up
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be blinded
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: No information about the outcome assessor
available
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
High risk Comment: Nine hundred and eighty-eight patients were
randomised. Of those 689 patients had at least two eval-
uations for the primary criterion HbA1c .
Quote: ”Three hundred and three patients discontinued
the study early
(164 SMBG; 139 control)“.
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
High risk Comment: The primary criterion was not estimable for
299 patients in the initial intention to treat analysis. A
modified intention to treat analysis is performed with
689 patients
Selective reporting (reporting bias) Unclear risk Comment: No trial registration or protocol available
Free of other bias?
Where groups similar at baseline?
Low risk Quote: ”No statistically significant difference was ob-
served between the two groups..“
Free of other bias?
Where co-interventions avoided or similar?
Low risk Quote: ”At visit 3 each GP could modify treatment of
their patients according to HbA1c , keeping with ANAES
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recommendations. At each consultation both groups
were equally informed“
Free of other bias?
Was the compliance acceptable in all
groups?
Unclear risk Quote: No statistically significant difference between the
two groups was found during the study in terms of diet
prescribed”. “Compliance to physical activity was similar
in both groups”
Comment: No information is available on performance
of SMBG
Kleefstra 2010
Methods Randomised controlled trial
Participants Country: The Netherlands
Number of participants: 41
Inclusion criteria:
• type 2 diabetes patients from the ZODIAC shared care project;
• 18 to 70 years of age;
• HbA1c between 7 and 8.5% at current annual check-up and inclusion;
• use of 1 or 2 different oral blood glucose lowering agents;
• oral blood glucose lowering agents were not changed during the past 3 months;
• no use of insulin;
• no use of devices for SMBG at the start of the study or in the previous 6 months;
• sufficient knowledge of the Dutch language to understand the requirements of the
study;
Mean age (years ± SD):
• SMBG: 59.5 ± 8.0
• Control: 58.7 ± 7.8
Diabetes duration (median years (q1-q3)):
• SMBG: 5.0 (4.0 - 7.0)
• Control: 8.0 (3.8 - 11.3)
Interventions 1. SMBG (n = 22): SMBG with no further education except for handling the device
and knowing which glucose values were considered normal or acceptable (fasting 4-8
mmol/L and post-prandial 4-10 mmol/L) and which abnormal.
2. Control (n = 18): Usual care provided by their own health care giver. No other
instructions were given, except for the explicit request not to use any form of SMBG
during the study.
Outcomes Primary outcome:
1. 1 HbA1c between groups.
Secondary outcomes:
1. Differences between groups in Health Related Quality of Life measures (SF-36;
WHO-5).
2. Diabetes related complaints (DSC-r).
3. Treatment satisfaction (DTSQ).
4. Cumulative incidence of (necessity to start) insulin therapy.
5. Bodyweight.
45Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kleefstra 2010 (Continued)
6. Body mass index.
Study details Duration of intervention: 12 months.
Publication details Language of publication: English
Funding: Roche Diagnostics
Publication status: Peer reviewed journal
Stated aim of study “To investigate the effects of SMBG on glycaemic control, quality of life and treatment
satisfaction in patients with T2DM not using insulin, who are in persistent moderate
glycaemic control”
Notes ZODIAC study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After inclusion.... a telephone call to a third party
was made, who had numbers ranging from 1 to 60 in
non-transparent envelopes, and was asked to draw an
envelope”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was done using an independent
third party”
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded to the intervention
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be blinded to the inter-
vention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Low risk Quote: “ All laboratory tests were performed in local hos-
pital laboratories,, where staff was unaware of treatment
allocation”
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Quote: “..one patient in the control group refused to
continue the study and withdrew”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Comment: Data from all patients initially randomised
were retrieved and analysed. (40 patients)
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Selective reporting (reporting bias) Low risk Comment: Primary outcomes are pre-specified in trial
register
Free of other bias?
Where groups similar at baseline?
High risk Quote: “BMI and diabetes duration where different be-
tween groups”
Free of other bias?
Where co-interventions avoided or similar?
Low risk Comment: No education was given to ensure there are
no education differences between groups
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “Of the 22 patients in the SMBG group 17 per-
formed at least 80% of the requested glucose registra-
tions”
Muchmore 1994
Methods Randomised controlled trial
Participants Country: USA
Number of participants: 23
Inclusion criteria:
• obese participants (BMI 27.5-44 kg/m2);
• aged 40 to 75 years;
• history of at least 1 year of non-insulin requiring diabetes;
• treated either with diet alone or diet plus oral sulphonylurea hypoglycaemic
agents;
• HbA1c within the range of 9.5%-13.5%;
• ability to comply with the protocol;
• absence of serious underlying medical or psychiatric illness, drug abuse or alcohol.
Exclusion criteria:
• participants who had performed SMBG within the previous 3 months;
• participants who have previously been instructed in dietary carbohydrate
counting.
Mean age (years ± SD):
• SMBG: 57.3 ± 8.0
• Control: 60.1 ± 7.3
Diabetes duration (years ± SD):
• SMBG: 5.7 ± 4.8
• Control: 5.2 ± 4.6
Interventions Four groups were formed over a period of 6 months, blocking for variables of weight,
HbA1c , diet vs. oral agent use, and sex.
Weeks -8 to 0: identical run-in for all 4 groups: weekly behavioural weight control
program + counselling by diabetes nurse educator + session with dietician. Follow-up
session educator at weeks 1, 3 and 24 and dietician at weeks 1 and 3
Week 0: randomly assignment to control or SMBG interventions
1. Intervention (n = 12): individual and group teaching on CarboHydrate counting
and SMBG, measured 6 times daily for 4 weeks. Reduced to pre- and postprandial
testing of a single meal per day for weeks 4-20. Beyond week 20, individual’s election
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and expense.
2. Control (n = 11): identical amount of attention, focus on general principles of
diabetes nutrition.Groups continued to meet weekly for weeks 0-4 and then every 4
weeks for weeks 4-20.
Outcomes 1. HbA1c , measured at weeks -8, 0, 16, 28 and 44.
2. Body weight measured at every patient encounter.
3. Diabetes Quality of Life Inventory at weeks 0, 24 and 44.
Study details Duration: 28 weeks (-8, 0-20 intervention) and follow-up till 44 weeks
Publication details Language of publication: English
Funding: Department of Academic Affairs, Scripps Clinic and Research Foundation
Publication status: Peer reviewed journal
Stated aim of study “To test the hypothesis that measuring and linking carbohydrate intake to incremental
postprandial SMBG results would allow to modify specific, proximate behaviours in the
management of type 2 diabetic patients”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “At week 0, groups I-III were randomly assigned
to control or SMBG interventions, group IV being as-
signed to control status in order to equalize the number
of groups in each intervention”
Comment: No information presented on randomisation
sequence.
Allocation concealment (selection bias) High risk Quote: “At week 0, groups I-III were randomly assigned
to control or SMBG interventions, group IV being as-
signed to control status in order to equalize the number
of groups in each intervention”
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be blinded
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Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Comment: It is not clear who assessed the primary out-
come, HbA1c
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
High risk Quote: “Of the 29 individuals recruited to the study, 6
dropped out prior to or at the time of randomisation...”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Unclear risk Comment: Even though endpoint data was available for
23 patients, no information is available on the number
of patients included in the analyses
Selective reporting (reporting bias) Unclear risk Comment: No trial registration or protocol publication
available
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “...treatment groups were well matched for all pre
randomisation variables except initial treatment modal-
ity....”
Free of other bias?
Where co-interventions avoided or similar?
Low risk Quote: “ Throughout the study, individuals remained
under medical care of their primary GP and decisions
on medical adjustments were coordinated through these
providers”
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “Subject compliance with protocol requirements
was good”
O’Kane 2008
Methods Prospective randomised controlled trial
Participants Country: Norhtern Ireland
Number of participants: 195
Inclusion criteria:
• Patients with newly diagnosed type 2 diabetes;
• < 70 years of age.
Exclusion criteria:
• secondary diabetes;
• use of insulin;
• previous use of SMBG;
• major illness within the previous six months;
• chronic kidney disease;
• chronic liver disease;
• alcohol misuse.
Mean age (years ± SD):
• SMBG: 57.7 ± 11.04
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• Control: 60.9 ± 11.5
Diabetes duration (years ± SD):
• SMBG: 0
• Control: 0
Interventions 1. SMBG (n = 96): SMBG and ongoing advice and support in interpretation of and
response to high or low readings.
2. Control (n = 88): no SMBG.
All patients received a structured education programme with nurse practitioners, dieti-
cians, podiatrist and medical staff at 3-monthly intervals and a treatment algorithm for
dietary and pharmacological management of glycaemia based on HbA1c targets. At each
visit aspects of diabetes care including glycaemic control (HbA1c) were reviewed.
Outcomes Primary outcome:
1. 1 HbA1c between groups.
2. Psychological indices (DTSQ, modified diabetes attitude scale, WBQ).
3. incidence of hypoglycaemia.
Secondary outcomes:
1. 1 body mass index between groups.
2. Use of oral hypoglycaemic drugs.
Study details Duration of intervention: 12 months.
Publication details Language of publication: English
Funding: Northern Ireland research and development office
Publication status: Peer reviewed journal
Stated aim of study “To investigate the effect of self monitoring on glycaemic control and attitudes and
satisfaction with treatment in patients with newly diagnosed type 2 diabetes”
Notes ESMON study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “.. with a randomly generated alloca-
tion code in consecutively numbered sealed
envelopes”
Allocation concealment (selection bias) Low risk Quote: “The study diabetes nurse at each hos-
pital site performed the treatment allocation”
Comment: Information is not presented if
these diabetes nurses are involved in the three
monthly patient reviews
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
High risk Comment: Patient cannot be blinded to the
intervention
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tion?
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be blinded
to the intervention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Low risk Quote: “Measurement of HbA1c was per-
formed in the local hospital laboratory with
a DCCT aligned HbA1c assay“. ”All labo-
ratory tests were also performed in the local
hospital laboratory, where staff were blinded
to treatment allocation”
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Low risk Comment: No patients were lost to follow up.
Quote: “4 patients failed to complete the
study (2 in each group)”
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
Low risk Quote: “The analysis was performed on an
intention to treat basis, with missing data im-
puted through the use of full information like-
lihood”
Selective reporting (reporting bias) Low risk Comment: All described pre-designated pri-
mary endpoints were reported in trial register
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “Therewas no significant difference in
baseline HbA1c , age, or sex between groups,
although participants in the self monitoring
group had a higher baseline body mass index”
Free of other bias?
Where co-interventions avoided or similar?
Low risk Quote: “Patients in both groups underwent
an identical structured educationprogramme.
..”
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “...63 patients in the intervention
group carried out at least 80%of the requested
blood glucose monitoring”
Comment: Compliance was defined as a
monitoring frequency of > 80% of that re-
quested
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Methods Multicenter, randomised controlled design
Randomised in blocks of eight.
Participants Country: Germany and Austria
Number of participants: 250 patients.
Inclusion criteria:
• type 2 diabetes patients;
• body mass index > 25 kg/m2;
• HbA1c values between 7.5 and 10%;
• treated either with diet alone or diet in combination with sulphonylureas or
metformin;
• age between 45 and 70 years;
• diabetes known for at least 3 months;
• participation in a diabetes educational program within the previous 2 years.
Exclusion criteria:
• incapable of maintaining an eating diary and of documenting their state of well-
being;
• sensomotor disturbances;
• used regular SMBG during the 6 months before the start of the study;
• participated in another clinical trial within 30 days before the start of the study-
pregnant or lactating females or without a safe contraception method;
• treatment with other antidiabetic agents such as insulin or with nonselective ß-
blockers, glucocorticoids, amphetamines, or anabolic agents;
• diet reduction during course of the study (< 1,000 kcal/day);
• serum creatinine > 3 mg/dl-serum transaminases > 50 units/L;
• serious underlying medical or psychiatric disorders or drug or alcohol abuse;
• use of acarbose.
Mean age (years ± SD):
• SMBG: 58.7 ± 7.6
• Control: 60.5 ± 6.6
Diabetes duration (years ± SD):
• SMBG: 5.5 ± 4.8
• Control: 5.2 ± 3.9
Interventions 1. SMBG (n = 113): Measurements of blood glucose 6 times on 2 days per week and
recordings of values obtained in a diary for blood glucose data and documentation of
eating habits and state of well-being. Continuing of using the glucometer during the
follow-up period.
2. Control (n = 110): non standardized counselling with a focus on their diet and
lifestyle.
Outcomes 1. HbA1c , determined using the DCA 2000 analyser.
2. Body weight.
3. Lipids and micro albumin.
4. Well-being and treatment satisfaction, measured by the Patient Well-being
Questionnaire and the Diabetes Treatment Satisfaction Questionnaire.
Laboratory parameters and body weight were assessed at randomisation and at 8, 16
and 24 weeks. Questionnaires were completed at randomisation, 24 weeks and follow-
up. HbA1c , body weight, SMBG acceptance, treatment satisfaction, and well-being were
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SMBG study group 2002 (Continued)
also assessed during two visits in the 6-month follow-up period
Study details Duration: 6 months and 6 months follow-up
Publication details Language of publication: English
Funding: Unrestricted grant from Bayer AG & Bayer Vital GmbH
Publication status:Peer reviewed journal
Stated aim of study “To investigate the effect of meal-related SMBG on diabetes control in non-insulin-
treated type 2 diabetic patients on a biometrical basis”
Notes SMBG study group
Data was extracted from 2 manuscripts: Schwedes 2002, Diabetes Care; Siebolds 2006,
Patient Education and Counseling.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “ a total of 250 patients were en-
rolled and randomised within blocks of
eight to receive one of the two treatments”
Comment: Information on randomisation
method is not presented
Allocation concealment (selection bias) Unclear risk Comment: Method of allocation conceal-
ment is not described
Blinding (performance bias and detection
bias)
Was the patient blinded to the interven-
tion?
High risk Comment: Patient cannot be blinded to the
intervention
Blinding (performance bias and detection
bias)
Was the care provider blinded to the inter-
vention?
High risk Comment: Care provider cannot be
blinded to the intervention
Blinding (performance bias and detection
bias)
Was the outcome assessor blinded to the
intervention?
Unclear risk Quote: “Assistants and nursing staff re-
ceived structured instructions on the cor-
rect use of the monitoring device, DCA
2000, and HemoCue and learned how to
supervise anddocument the correct use and
documentation by the patients“
Incomplete outcome data (attrition bias)
Was the drop-out rate described and ac-
ceptable?
Unclear risk Comment: Twenty-seven patients were not
included in the analysis, but reasons for ex-
clusion are not described
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SMBG study group 2002 (Continued)
Incomplete outcome data (attrition bias)
Was an intention to treat analysis per-
formed?
High risk Quote: ”Of the 250 randomised patients,
223 per-protocol analysis“
Quote: ”Per-protocol analysis was per-
formed as the main efficacy analysis’
Selective reporting (reporting bias) Unclear risk Comment: Although planned no informa-
tion on the follow-up data is reported
Free of other bias?
Where groups similar at baseline?
Low risk Quote: “The baseline demographic char-
acteristics compared well for both groups”.
“There were no statistically significant dif-
ferences regarding baseline efficacy param-
eters”
Free of other bias?
Where co-interventions avoided or similar?
High risk Quote: “SMBG patients received a defined
counselling algorithm...”
“The control group received non standard-
ized counselling with a focus on their diet
an lifestyle...”
Comment: The intervention group re-
ceived counselling focused on psycholog-
ical aspects and the control group coun-
selling was non standardized. Both inter-
ventions could therefore cause bias. Fur-
thermore, no details are givenwhether both
groups had different nurses delivering the
counselling
Free of other bias?
Was the compliance acceptable in all
groups?
Low risk Quote: “Patients were included in the anal-
ysis if theymet protocol criteria, completed
the entire study, showed valid efficacy pa-
rameter measurements and were over 70%
compliant”
Comment: Twenty-seven out of 250 were
excluded.
SMBG = Self-Monitoring of Blood Glucose; SMUG = Self-Monitoring of Urine Glucose
DCCT= Diabetes Control and Complications Trial
BMQ: Beliefs about Medicine Questionnaire; DSC-r: Diabetes Symptom Checklist; DSCAQ: Diabetes Self-care Activities Questionnaire;
DTSQ:Diabetes Treatment SatisfactionQuestionnaire;DQOL:DiabetesQualityOf Life Inventory; EQ5D:EuroQol-5D;MARS:Medication
Adherence Reporting Scale; SF-36: Short-Form 36; WBQ-12/22: Well Being Questionnaire-12/22; WHO-5: World Health Organization-5.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelgadir 2006 not randomised, also included patients with type 1 diabetes
Atsumi 1997 abstract, no detailed information could be retrieved
Bajkowska-Fiedziukiewicz 2008 not randomised
Chidum 2011 after 3 months follow-up, no data on control group
Cho 2006 intervention group received an Internet based SMBG system. SMBG not the main intervention
Davidson 2004 abstract that has been identified as an already included study
Drouin 2002 abstract that has been identified as an already included study
Franciosi 2005 not randomised
Gallego 2007 not randomised
Hoffmann 2011 not randomised
Johnson 2006 control group is using SMBG
Kelly 2007 non-relevant study design (letter to the editor)
Kwon 2004 both groups received SMBG; the intervention group received an Internet-based SMBG system
and the control group just the SMBG. SMBG was not the main intervention
Laffel 2007 insulin treated patients
Lecomte 2008 not randomised, also included patients with type 1 diabetes
Lim 2011 included insulin treated patients
Mohan 2010 both intervention and control used SMBG
Moreland 2006 also included patients with type 1 diabetes and insulin users
O’Kane 2006 abstract that has been identified as an already included study
Pignone 2009 reprint of already included trial
Polonsky 2011 control group uses SMBG also
Scherbaum 2008 control group uses SMBG also
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Shiraiwa 2010 detailed information on trial could not be retrieved (letter to the editor)
Tengblad 2007 not randomised
Wen 2004 not randomised, no control group, SMBG not the prime intervention
Wysocki 1989 not randomised
Characteristics of ongoing studies [ordered by study ID]
Bergenstal 2005
Trial name or title Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
Methods Allocation: Randomised, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention
Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Participants Type 2 diabetes patients with the following criteria:
• Treatment with diet and exercise alone or with the addition of 1 or 2 oral agent
• Enrolled in Type 2 BASICS program
• A1c between 7.0 and 11%, inclusive
• Able to understand spoken English
Exclusion Criteria:
• Insulin therapy
• Unable/unwilling to perform SMBG
• Participating in another research study
• Currently performing SMBG > 3 times/week
Interventions Behavioral: frequency of self monitoring blood glucose
Outcomes Primary: HbA1c 2 years
Secondary: blood glucose testing frequency 2 years
Starting date September 2004
Contact information Richard M Bergenstal, MD, Principal Investigator, Park Nicollet Institute/International Diabetes Center
International Diabetes Center
Minneapolis
Minnesota
55416
Notes
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Malanda 2009
Trial name or title Effect of self-monitoring of glucose in non-insulin treated patients with type two diabetes: The In Control
Trial
Methods Three-armed randomised controlled active parallel group trial
Participants Type 2 diabetes patients with the following criteria:
• known disease duration of over 1 year
• recent HbA1c 7.0% or higher
• treated with diet and/or oral hypoglycaemic agents
• do not require insulin at inclusion
• aged between 45 and 75 years
• used SMBG or SMUG less than 3 times in the previous year
Interventions • intervention group A, performing SMBG with specific SMBG education, in addition to usual diabetes
care provided by the regional diabetes care system.
• intervention group B, performing SMUG with specific SMUG education, in addition to usual
diabetes care provided by the regional diabetes care system.
• control group receiving usual diabetes care provided by the regional diabetes care system
Outcomes Primary outcome measures:
• changes in diabetes specific emotional distress
• changes in self-efficacy.
Secondary outcomes
• changes in glycaemic control,
• changes in patient treatment satisfaction,
• changes in physical activity,
• changes in health status,
• status of depression,
• occurrence of hypoglycaemia,
• cost-effectiveness and cost-utility.
• process evaluation
Starting date 01-07-2007
Contact information VU Medical Centre Amsterdam
EMGO-Instituut
Afdeling Huisartsgeneeskunde
g.nijpels@vumc.nl
Notes IN CONTROL study
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D A T A A N D A N A L Y S E S
Comparison 1. SMBG vs control (6 months follow-up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HbA1c 9 2324 Mean Difference (IV, Random, 95% CI) -0.26 [-0.39, -0.13]
Comparison 2. SMBG vs control (12 months follow-up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HbA1c 2 493 Mean Difference (IV, Random, 95% CI) -0.13 [-0.31, 0.04]
Comparison 3. SMBG vs control (newly diagnosed patients, 6 month follow-up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HbA1c 2 345 Mean Difference (IV, Random, 95% CI) -0.53 [-1.06, -0.01]
Comparison 4. SMBG vs control (newly diagnosed patients, 12 months follow-up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HbA1c 2 345 Mean Difference (IV, Random, 95% CI) -0.52 [-0.89, -0.14]
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Comparison 5. SMBG vs SMUG (6 months follow-up)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HbA1c 2 194 Mean Difference (IV, Random, 95% CI) -0.17 [-0.96, 0.61]
Analysis 1.1. Comparison 1 SMBG vs control (6 months follow-up), Outcome 1 HbA1c.
Review: Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Comparison: 1 SMBG vs control (6 months follow-up)
Outcome: 1 HbA1c
Study or subgroup SMBG Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Barnett 2008 311 -1.15 (1.14) 299 -0.91 (1.29) 22.0 % -0.24 [ -0.43, -0.05 ]
Davidson 2005 43 -0.8 (1.6) 45 -0.6 (2.1) 2.6 % -0.20 [ -0.98, 0.58 ]
DiGEM trial 2007 (1) 301 -0.15 (0.81) 152 -0.08 (0.73) 27.7 % -0.07 [ -0.22, 0.08 ]
Fontbonne 1989 68 -0.36 (3.14) 68 -0.5 (1.54) 2.3 % 0.14 [ -0.69, 0.97 ]
Franciosi 2011 46 -1.2 (0.81) 16 -0.7 (0.7) 7.9 % -0.50 [ -0.92, -0.08 ]
Guerci 2003 345 -0.9 (1.54) 344 -0.5 (1.54) 18.3 % -0.40 [ -0.63, -0.17 ]
Kleefstra 2010 22 -0.18 (0.67) 18 0.07 (0.75) 7.0 % -0.25 [ -0.70, 0.20 ]
Muchmore 1994 12 -1.54 (1.46) 11 -0.85 (1.87) 0.9 % -0.69 [ -2.07, 0.69 ]
SMBG study group 2002 113 -1 (1.08) 110 -0.54 (1.41) 11.3 % -0.46 [ -0.79, -0.13 ]
Total (95% CI) 1261 1063 100.0 % -0.26 [ -0.39, -0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.29, df = 8 (P = 0.19); I2 =29%
Test for overall effect: Z = 3.99 (P = 0.000067)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours SMBG Favours Control
(1) Both intervention groups are combined
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Analysis 2.1. Comparison 2 SMBG vs control (12 months follow-up), Outcome 1 HbA1c.
Review: Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Comparison: 2 SMBG vs control (12 months follow-up)
Outcome: 1 HbA1c
Study or subgroup SMBG Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
DiGEM trial 2007 (1) 301 -0.15 (0.78) 152 0 (1.02) 89.1 % -0.15 [ -0.33, 0.03 ]
Kleefstra 2010 22 -0.1 (0.9) 18 -0.1 (0.8) 10.9 % 0.0 [ -0.53, 0.53 ]
Total (95% CI) 323 170 100.0 % -0.13 [ -0.31, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours SMBG Favours Control
(1) Both intervention groups are combined
Analysis 3.1. Comparison 3 SMBG vs control (newly diagnosed patients, 6 month follow-up), Outcome 1
HbA1c.
Review: Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Comparison: 3 SMBG vs control (newly diagnosed patients, 6 month follow-up)
Outcome: 1 HbA1c
Study or subgroup SMBG Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Dur n 2010 99 -0.68 (0.45) 62 0.05 (0.37) 64.5 % -0.73 [ -0.86, -0.60 ]
O’Kane 2008 96 -1.81 (2.1) 88 -1.64 (2.08) 35.5 % -0.17 [ -0.77, 0.43 ]
Total (95% CI) 195 150 100.0 % -0.53 [ -1.06, -0.01 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 3.16, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours SMBG Favours Control
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Analysis 4.1. Comparison 4 SMBG vs control (newly diagnosed patients, 12 months follow-up), Outcome 1
HbA1c.
Review: Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Comparison: 4 SMBG vs control (newly diagnosed patients, 12 months follow-up)
Outcome: 1 HbA1c
Study or subgroup SMBG Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Dur n 2010 99 -0.56 (0.52) 62 0.07 (0.6) 73.3 % -0.63 [ -0.81, -0.45 ]
O’Kane 2008 96 -1.88 (2.06) 88 -1.68 (2.11) 26.7 % -0.20 [ -0.80, 0.40 ]
Total (95% CI) 195 150 100.0 % -0.52 [ -0.89, -0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 2.71 (P = 0.0067)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours SMBG Favours Control
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Analysis 5.1. Comparison 5 SMBG vs SMUG (6 months follow-up), Outcome 1 HbA1c.
Review: Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin
Comparison: 5 SMBG vs SMUG (6 months follow-up)
Outcome: 1 HbA1c
Study or subgroup SMBG SMUG
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Allen 1990 27 -2 (3.4) 27 -2 (2.4) 24.9 % 0.0 [ -1.57, 1.57 ]
Fontbonne 1989 68 -0.36 (3.14) 72 -0.13 (2.2) 75.1 % -0.23 [ -1.13, 0.67 ]
Total (95% CI) 95 99 100.0 % -0.17 [ -0.96, 0.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours SMBG Favours SMUG
A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Characteris-
tic
Study ID
Intervention
(s) & control
(s)
Screened (n) Randomised
(n)
ITT (n) Randomised
patients finish-
ing study (%)
Finishing study
(n)
Comments
Allen 1990 SMBG - - - - 27
SMUG - - - - 27
(total) - 61 - 89 54 Seven patients
dropped
out (5were inap-
propriately ran-
domised, 2 gave
no reasons for
drop-out)
Barnett 2008 SMBG - 311 311 87 271
Control - 299 299 83 248
(total) - 610 610 85 519
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Table 1. Overview of study populations (Continued)
Davidson
2005
SMBG - - 43 - 43
Control - - 45 - 45
(total) 89 89 88 99 88 Initially 89 pa-
tients were ran-
domised.
One patient did
not return after
randomisation.
It is not stated in
which group this
patient was ran-
domised
DiGEM trial
2007
SMBG more
intensive
- 151 151 89 134
SMBG less in-
tensive
- 150 150 91 136
Control - 152 152 83 126
(total) 364,527 453 453 87 396
Durán 2010 SMBG - 130 99 76 99 Twenty-nine pa-
tients partic-
ipated in an ex-
ercise supervised
program and
were excluded.
Two were lost to
follow-up
Control - 65 62 95 62 Three patients
were lost to fol-
low-up
(total) 250 195 161 83 161
Fontbonne
1989
SMBG - 68 - 82 56 Twelve patients
were lost to fol-
low-up
SMUG - 72 - 75 54 Eighteen pa-
tients were lost
to follow-up
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Table 1. Overview of study populations (Continued)
Control - 68 - 79 54 Fourteen pa-
tients were lost
to follow-up
(total) - 208 - 79 164
Franciosi
2011
SMBG - 46 46 91 42
Control - 16 16 94 15
(total) - 62 62 92 57
Guerci 2003 SMBG - 510 345 68 346
Control - 478 344 71 339
(total) - 988 689 69 685 Two-hun-
dred and forty
patients had a
reason for dis-
continuation
Kleefstra 2010 SMBG - 22 22 100 22
Control - 19 19 95 18 One pa-
tient withdrew
consent
(total) - 41 41 98 40
Muchmore
1994
SMBG - 15 - 80 12 Three patients
dropped out
Control - 14 - 79 11 Three patients
dropped out
(total) 40 29 - 79 23
O’Kane 2008 SMBG - 96 96 98 94 Two patients
withdrew from
intervention
Control - 88 88 98 86 Two patients
withdrew from
intervention
(total) 212 184 184 98 180
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Table 1. Overview of study populations (Continued)
SMBG study
group 2002
SMBG - - - - 113
Control - - - - 110
(total) 250 250 - 89 223 Per
protocol analysis
performed
total 3259 80 2590
“-” denotes not reported
ITT = intention-to-treat analysis; SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose
A P P E N D I C E S
Appendix 1. Search strategies
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) substitutes one or no characters; tw = text word;
pt = publication type; sh = MeSH; adj = adjacent
MEDLINE
1. exp Blood glucose self-monitoring/
2. self monitor$.ti,ab.
3. exp Blood Glucose/ or (blood adj glucos$).ti,ab. or (blood adj sugar$).ti,ab.
4. 1 or (2 and 3)
5. exp Diabetes mellitus, non insulin dependent/ or exp Insulin resistance/
6. (impaired glucose toleran$ or glucose intoleran$ or insulin resistan$).ti,ab.
7. (obes$ adj2 diabet$).ti,ab.
8. (mody or niddm).ti,ab.
9. (diabet$ and (non insulin$ depend$ or noninsulin$ depend$ or noninsulindepend$ or non insulindepend$ or noninsulinsdepend$
or non insulinsdepend$)).ti,ab.
10. ((typ$ 2 or typ$ II) adj diabet$).ti,ab.
11. ((ketoresist$ or keto$ resist$ or nonketo$ or non keto$) adj diabet$).ti,ab.
12. ((adult$ or matur$ or late or slow or stabl$) adj diabet$).ti,ab.
13. ((plurimetabolic$ or metabolic) adj syndrom$).ti,ab.
14. (insulin$ defic$ adj relativ$).ti,ab.
65Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
15. 6 or 11 or 7 or 9 or 12 or 14 or 8 or 10 or 13 or 5
16. exp Diabetes insipidus/
17. (exp Child/ or exp Infant/) not (exp adult/ or exp adolescent/)
18. (4 and 15) not (16 or 17)
19. (randomised controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab.
or trial.ab. or groups.ab.
20. clinical trial.mp. or clinical trial.pt. or random$.mp. or tu.xs.
21. Cross-over Studies/ or exp Double-blind method/ or exp Single-blind method/ or exp Control groups/ or exp Random Allocation/
or exp Evaluation studies/ or exp Comparative study/
22. 18 and (19 or 20 or 21)
23. limit 22 to yr=“2004 -Current”
EMBASE
1. ((ketoresist$ or keto$ resist$ or nonketo$ or non keto$) adj diabet$).ti,ab.
2. ((adult$ or matur$ or late or slow or stabl$) adj diabet$).ti,ab.
3. (insulin$ defic$ adj relativ$).ti,ab.
4. ((plurimetabolic$ or metabolic) adj syndrom$).ti,ab.
5. ((typ$ 2 or typ$ II) adj diabet$).ti,ab.
6. (diabet$ and (non insulin$ depend$ or noninsulin$ depend$ or noninsulindepend$ or non insulindepend$ or noninsulin?depend$
or non insulin?depend$)).ti,ab.
7. (mody or niddm).ti,ab.
8. (obes$ adj2 diabet$).ti,ab.
9. (impaired glucose toleran$ or glucose intoleran$ or insulin resistan$).ti,ab.
10. exp Non insulin dependent diabetes mellitus/ or exp Insulin resistance/ or exp Diabetic obesity/
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12. exp Blood glucose monitoring/
13. self monitor$.ti,ab.
14. exp Glucose blood level/ or (blood adj glucos$).ti,ab. or (blood adj sugar$).ti,ab.
15. 13 and 14
16. 12 or 15
17. 11 and 16
18. 17 not exp Diabetes insipidus/
19. exp Randomized controlled trial/ or exp Controlled clinical trial/ or exp Crossover-procedure/ or exp Double-blind procedure/
or exp Single-blind procedure/ or exp Control group/ or exp Randomization/ or exp Evaluation/ or exp Comparative study/
20. (random$ or factorial$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$
or volunteer$).ti,ab.
21. limit 18 to (human and yr=“2004 - 2010”)
22. 21 not (exp Child/ not exp adult/)
23. limit 22 to “treatment (1 term high sensitivity)”
24. 23 or (22 and (19 or 20))
The Cochrane Library
(CENTRAL)
1. (impaired NEXT glucose NEXT toleran* OR glucose NEXT intoleran* OR insulin* NEXT resistan* OR obes* NEAR diabet*
OR MODY OR NIDDM) in Clinical Trials
2. (diabet* AND (non NEXT insulin* NEXT depend* OR noninsulin* NEXT depend* OR noninsulindepend* OR non NEXT
insulindepend* OR noninsulinsdepend* OR non NEXT insulinsdepend*)) in Clinical Trials
3. (typ* NEXT 2 OR typ* NEXT II) NEAR/2 diabet* in Clinical Trials
4. ((keto* NEXT resist*) OR nonketo*) NEAR/2 diabet* in Clinical Trials
5. (adult* OR matur* OR late OR slow or stabl*) NEAR/2 diabet* in Clinical Trials
6. (insulin* NEXT defic* NEAR relativ*) in Clinical Trials
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(Continued)
7. (plurimetabolic NEXT syndrom*) in Clinical Trials
8. (blood NEAR/2 glucos* OR blood NEAR/2 sugar*) AND (self NEXT monitor* OR selfmonitor*) in Clinical Trials
9. (( #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 ) AND #8), from 2004 to 2010
(NHSEED, CDSR, DARE, HTA)
1. (glucos* OR sugar* OR insulin* OR diabet*) and (selfmonitor* OR self-monitor*), from 2004 to 2010
PsycINFO
1 (glucose or sugar).mp. or Blood sugar/ (7319)
2 Self monitor*.mp. or Self monitoring/ (3801)
3 1 and 2 (98)
4 limit 3 to yr=“2004 -Current” (54)
Current Controlled Trials
1. (monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)
2. (self ) AND (monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)
3. (self-monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)
4. (self monitoring) AND (glucose OR sugar) AND (diabetes OR diabetic)
Appendix 2. Baseline characteristics of included studies
Charac-
teristic
Study ID
Partici-
pat-
ing popu-
lation
Male (%) Female
(%)
Age
(years)
HbA1c
(%)
Bodymass
index (kg/
m2)
Diabetes
duration
(years)
Dura-
tion of in-
tervention
(weeks)
Dura-
tion of fol-
low-up
(weeks)
Allen 1990 SMUG 100 0 57.9 ± 10.
7
11.7 ± 3.0 - 9.0 ± 10.3 26 26
SMBG 100 0 58.2 ± 9.7 12.4 ± 3.3 - 6.8 ± 6.5 26 26
Barnett
2008
Control 51.8 47.8 55.9 ± 9.3 8.1 ± 0.84 30.3 ± 5.0 2.8 ± 4.5 27 27
SMBG 48.2 50.5 56.1 ± 9.1 8.1 ± 0.89 30.5 ± 5.3 2.8 ± 3.7 27 27
Davidson
2005
Control 31.1 68.9 50.9 ± 11.
0
8.5 ± 2.2 33.4 ± 7.0 5.8 ± 5.8 26 26
SMBG 20.9 79.1 49.8 ± 11.
2
8.4 ± 2.12 31.7 ± 6.7 5.5 ± 4.7 26 26
DiGEM
trial 2007
Control 55.9 44.1 66.3 ± 10.
2
7.5 ± 1.09 30.9 ± 6.1 3 (2 to 6) 52 52
SMBG less
intensive
58.7 41.3 65.2 ± 10.
6
7.4 ± 1.02 31.9 ± 6.2 3 (2 to 7) 52 52
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SMBG
more
intensive
57.6 42.4 65.6 ± 9.9 7.5 ± 1.12 31.0 ± 5.3 3 (2 to 6) 52 52
Durán
2010
Control 46.8 53.2 64.7 ± 9.6 6.7 ± 0.54 29.8 ± 5.1 0 52 52
SMBG 45.5 54.5 62.5 ± 10.
4
6.7 ± 0.17 30.1 ± 5.2 0 52 52
Franciosi
2011
Control 87.5 12.5 48.7± 0.6 7.9 ± 0.6 30.2 ± 3.9 3.2 ± 4.4 26 26
SMBG 69.6 30.4 48.9 ± 0.5 7.9 ± 0.6 31.8 ±4.8 3.4 ± 3.5 26 26
Fontbonne
1989
Control 58.8 41.2 56.3 ± 9.1 8.2 ± 2.5 27.0 ± 4.1 12.7 ± 0.8 26 26
SMUG 72.2 27.8 54.9 ± 10.
2
8.6 ± 2.5 26.0 ± 3.4 13.3 ± 6.8 26 26
SMBG 52.9 47.1 54.5 ± 10.
7
8.2 ± 2.5 27.1 ± 4.1 12.2 ± 6.6 26 26
Guerci
2003
Control 56.6 43.4 62.2 ± 9.1 8.9 ± 1.3 29.7 ± 4.8 8.4 ± 6.6 24 26
SMBG 53.7 46.3 60.9 ± 9.4 9.0 ± 1.3 30.4 ± 6.1 7.7 ± 6.3 24 26
Kleefstra
2010
Control 72.2 27.8 58.7 ± 7.8 7.7 ± 0.4 32.7 ± 5.8 8.0 (3.8 to
11.3)
52 52
SMBG 54.5 45.5 59.5 ± 8.0 7.6 ± 0.5 29.0 ± 4.6 5.0 (4.0 to
7.0)
52 52
Much-
more
1994
Control 45.5 54.5 60.1 ± 7.3 10.5 ± 1.5 33.3 ± 4.3 5.2 ± 4.6 28 44
SMBG 33.3 66.7 57.3 ± 8.0 10.3 ± 1.1 35.1 ± 4.8 5.7 ± 4.8 28 44
O’Kane
2008
Control 63.6 36.4 60.9 ± 11.
5
8.6 ± 2.3 32.0 ± 6.2 0 52 52
SMBG 57.3 42.7 57.7 ± 11.
0
8.8 ± 2.1 34.0 ± 7.0 0 52 52
SMBG
study
group
Control 51.8 48.2 60.5 ± 6.6 8.4 ± 0.75 31.9 ± 5.5 5.2 ± 3.9 26 52
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2002
SMBG 52.2 47.8 58.7 ± 7.6 8.5 ± 0.86 31.0 ± 4.6 5.5 ± 4.8 26 52
Footnotes
values are displayed as mean (SD), median (q1 to q3) or proportion of patients
“-” denotes not reported
SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose
Appendix 3. Overview of trial SMBG education programmes
Characteristic
Study ID
Intervention (SMBG)
instructions
SMBG
frequency
Feedback on
SMBG
Education Diaries
Allen 1990 SMUG Patients were in-
dividually
instructed in the
prescribed test-
ing technique,
which they prac-
tised for 7 to 10
days
A measurement
before each meal
every other day
Ongo-
ing feedback by
physician
Dietary instruc-
tions based on
weight and ac-
tivity level and
focused on in-
creasing fiber in-
take by a dieti-
cian; Instruction
booklet includ-
ing ADA’s ex-
change list for
food fiber classi-
fication
Food and exer-
cise diaries
SMBG
Barnett 2008 Control No self-monitor-
ing
All randomised
patients received
diet and lifestyle
advice, re-
inforced at each
clinic visit;
None
SMBG Instructions in-
cluded informa-
tion on how to
use,
check the glu-
cosemetre, when
to take measure-
ments and what
to do in the
event of hypo-
glycaemia
5 measurements
a day (before ev-
erymeal, 2h after
the main meal
and before bed-
time) on 2 days a
week (one work-
ing day, one non-
working day).
Once a month 3
postprandial
No information
available
All randomised
patients received
diet and lifestyle
advice, re-
inforced at each
clinic visit; Writ-
ten Information
on the manage-
ment of hypo-
glycaemia; blood
Hypoglycaemia
and food diary
69Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
measurements
are asked
glucose
Davidson 2005 Control No self-monitor-
ing
5 dietician visits
and nutritional
counselling us-
ing glucose val-
ues and meal de-
scriptions on the
effects of meal
components and
portion sizes on
rise in postpran-
dial glucose lev-
els
Food diary
SMBG No information
available
6 measurements
a day around
meals (pre- and
2h post prandial)
for 6 days a week
The nurse used
SMBG values to
make therapeu-
tic decisions fol-
lowing detailed
algorithms
DiGEM trial
2007
Control No self-moni-
toring
Be-
haviour change
techniques based
applied using a
goal setting and
review approach
and
discussed within
the frame-
work of the com-
monsense model
of illness repre-
sentation. Con-
tinued at follow-
up visits
Self-care
goals and strate-
gies; activity;
Less intensive
SMBG
2 days a week, 3
tests daily (1 af-
ter fasting, 2 be-
fore meal or 2
hours after meal)
Instruc-
tion to aim for 4-
6mmol/l fasting
and 6-8 mmol/l
after meals. Re-
sults were inter-
preted by
the study nurse
at follow-up
Self-
care goals and
strategies; activ-
ity; blood glu-
cose results;
More intensive
SMBG
2 days a week, 3
tests daily (1 af-
ter fasting, 2 be-
fore meal or 2
hours after meal)
Training and on-
going support in
interpreting and
applying the re-
sults of blood
glucose readings
to enhance moti-
vation andmain-
tain adherence to
diet physical ac-
tivity and medi-
cation regimens
Durán 2010 Control No self-moni-
toring
Lifestyle inter-
ventions based
on a 2h individ-
ual session, re-
inforced at each
follow-up visit
None
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SMBG 1h session with
information how
to perform mea-
surements
and how to col-
lect data
6 measurements
a day around
meals (pre- and
2h post pran-
dial) and after
change in med-
ication, every 3
days
Review-
ing of know-how
and evaluationof
possible con-
founding factors
on recorded glu-
cose values
Franciosi 2011 Control No self-monitor-
ing
Standard coun-
selling with fo-
cus on diet and
lifestyle, every 3
months
SMBG Specific educa-
tion how to per-
form SMBG
2
weekly, pre-and
2h post prandial
measurements
around onemain
meal (1st day
breakfast,
3rd day lunch,
5th day dinner)
Structured tele-
phone interviews
every month dis-
cussing relations
for elevated glu-
cose val-
ues and quality/
quantity of foods
and exercise
Standard-
ized specific ed-
ucation address-
ing how to per-
form SMBG, ho
tomodify diet an
level of physical
activity accord-
ing to blood glu-
cose levels and
the actions to
undertake in case
of abnormal val-
ues. Povided by
diabetes nurses
Food, blood glu-
cose and physical
activity diary
Fontbonne 1989 Control No ed-
ucation, except
for (renewal of )
personalized di-
etary recommen-
dations
SMUG Instructions how
to perform
SMUG
Twice every
other day, fasting
and 2 hours af-
ter the evening
meal, with an ex-
tra test 2 hours
after lunch on
Sundays
Ongo-
ing feedback by
physician
Glucose diaries
SMBG Instructions how
to perform
SMBG
Twice every
other day, on the
first urine voided
in the
morning and the
first urine voided
after the evening
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meal, with an
extra test after
lunch on Sun-
days
Guerci 2003 Control Edu-
cation on weight
loss and physical
activity
SMBG Patients received
specific
initial training in
SMBG given by
their general
practitioner
At least 6 mea-
surements
a week on 3 dif-
ferent days of the
week, including
weekends
Ongoing
feedback at each
consultation
Kleefstra 2010 Control Explicit request
not to self-mon-
itor during the
study
No education
SMBG Information on
how to handle
the device
and target glu-
cose values were
provided
4 mea-
surements a day
(1 fasting, 3post-
prandial), twice a
week on a week-
day and a week-
end day
No information
available
Glucose diaries;
Muchmore 1994 Control No self-moni-
toring
8-weeks be-
havioral weight
control program
before onset of
the intervention;
individual coun-
selling by dia-
betes nurse ed-
ucator and in-
dividual sessions
with a dietician
at baseline and at
follow-up. From
baseline, sessions
on general prin-
ciples of diabetes
nutri-
tion according to
ADA guidelines
SMBG SMBG training
by diabetes nurse
6 measurements
a day (pre- and
No information
available
8-weeks be-
havioral weight
Food, carbohy-
drate and blood
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educator given
in individual and
group sessions
2h postprandi-
ally) for 4 weeks.
Subsequently, 2
measurements a
day (pre- and 2h
postprandially)
for 16 weeks
control program
before onset of
the intervention;
individual coun-
selling by dia-
betes nurse ed-
ucator and in-
dividual sessions
with a dietician
at baseline and at
follow-up. From
baseline individ-
ual
and group teach-
ing on carbohy-
drate counting
glucose diary
O’Kane 2008 Control No self-moni-
toring
Struc-
tured education
programme in-
volving diabetes
nurse practition-
ers, dieti-
cians, podiatrists
and medical staff
None
SMBG Instructions in
the use of a glu-
cose monitor
Four fasting and
4 postprandial
measurements
per week
Ongoing advice
and support in
interpretation of
and response to
glucose measure-
ments
SMBG study
group 2002
Control No self-moni-
toring
Non-standard-
ized counselling
focused on diet
and lifestyle
SMBG Instructions
in self-monitor-
ing and a request
to continue of
using the glucose
meter during the
follow-up period
6 measurements
a day around
meals (pre- and
2h post pran-
dial) for 2 days a
week (one week-
day and a Sun-
day)
No information
available
SMBG educa-
tion and prede-
fined counselling
al-
gorithm on self-
perception, self-
reflection and
self regulation
Combined food,
well-being and
glucose diary
Footnotes
SMBG = self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose
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Appendix 4. Effects of SMBG in patients with type 2 diabetes who are not using insulin (biochemical
outcomes)
Charac-
teristic
Study
ID
Inter-
vention
In-
cluded
patients
(n)
Baseline
HbA1c
(%)
6
months
HbA1c
(%)
12
months
HbA1c
(%)
6
months
change
in
HbA1c
(%)
12
months
change
in
HbA1c
(%)
Baseline
FPG
(mmol/
L)
6
months
FPG
(mmol/
L)
6
months
change
in FPG
(mmol/
L)
Patients
report-
ing hy-
pogly-
caemic
events
(%)
Allen
1990
SMUG 27 11.7 ±
3.0
9.7 ± 2.
6
-2.0 ± 2.
4
12.0 ± 2.
6
10.5 ± 3.
0
-1.5 ± 2.
8
SMBG 27 12.4 ± 3.
3
10.4 ±
2.9
-2.0 ± 3.
4
12.0 ± 2.
4
10.6 ± 3.
6
-1.4 ± 3.
2
Barnett
2008
Control 299 8.1 ± 0.
84
7.2 ± 1.
22
-0.9 ± 1.
29
9.0 ± 2.5 8.0 -1.0 ± 2.
5
7
SMBG 311 8.1 ± 0.
89
7.0 ± 0.
97
-1.2 ± 1.
14 ∗
8.9 ± 2.3 7.6 -1.3 ± 2.
5
8.7
David-
son
2005
Control 45 8.5 ± 2.
2
7.9 ± 1.
5
-0.6 ± 2.
1
SMBG 43 8.4 ± 2.
12
7.5 ± 1.
55
-0.8 ± 1.
6
DiGEM
trial
2007
Control 152 7.5 ± 1.
09
7.4 ± 1.
00
7.5 ± 1.
20
-0.1 ± 0.
73
0.0 ± 1.
02
9.2
less in-
tensive
SMBG
150 7.4 ± 1.
02
7.3 ± 1.
02
7.3 ± 0.
88
-0.1 ± 0.
84
-0.1 ± 0.
82
22
more in-
tensive
SMBG
151 7.5 ± 1.
12
7.3 ± 1.0 7.4 ± 1.
05
-0.2 ± 0.
79
-0.2 ± 0.
73
28.5
Durán
2010
Control 62 6.7 ± 0.
54
6.8 ± 0.
84
6.8 ± 0.
52
0.1 ± 0.
37
-0.1 ± 0.
60
-
SMBG 99 6.7 ± 0.
17
6.1 ± 0.
43
6.1 ± 0.
52
-0.7 ± 0.
45 ∗
-0.6 ± 0.
52 ∗
-
Fran-
ciosi
2011
Control 16 7.9 ± 0.6 7.2 ± 0.8 0.7 ± 0.2 0
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SMBG 46 7.9 ± 0.6 6.7 ± 0.7 1.2 ± 0.1
∗
0
Font-
bonne
1989
Control 68 8.2 ± 2.
5
7.7 -0.5 ± 1.
5
SMUG 72 8.6 ± 2.
5
8.5 -0.1 ± 2.
2
SMBG 68 8.2 ± 2.
5
7.8 -0.4 ± 3.
1
Guerci
2003
Control 344 8.9 ± 1.
3
8.4 ± 1.
4
-0.5 ± 1.
5
7.5 ± 4.8 6.9 ± 4.6 -0.6 5.2
SMBG 345 9.0 ± 1.
3
8.1 ± 1.
6
-0.9 ± 1.
5 *
7.2 ± 5.1 6.7 ± 4.8 -0.5 10.4
Kleefstra
2010
Control 18 7.7 ± 0.4 7.7 ± 0.6 7.5 ± 0.5 0.07 ±
0.75
-0.1 ± 0.
8
SMBG 22 7.6 ± 0.5 7.4 ± 0.7 7.5 ± 0.8 -0.2 ± 0.
67
-0.1 ± 0.
9
Much-
more
1994
Control 11 10.5 ±
1.5
9.6 ± 2.
09
-0.9 ± 1.
87
SMBG 12 10.3 ±
1.1
8.8 ± 1.
7
-1.5 ± 1.
46
O’Kane
2008
Control 88 8.6 ± 2.3 7.0 ± 1.1 6.9 ± 1.2 -1.6 ± 2.
08
-1.7 ± 2.
11
-
SMBG 96 8.8 ± 2.1 7.0 ± 0.9 6.9 ± 0.8 -1.8 ± 2.
1
-1.9 ± 2.
06
-
SMBG
study
group
2002
Control 110 8.4 ± 0.
75
7.8 ± 1.
52
-0.5 ± 1.
4
SMBG 113 8.5 ± 0.
86
7.5 ± 1.
27
-1.0 ± 1.
1*
Footnotes
∗ statistically significant difference between groups (P < 0.05)
“-” denotes not reported
FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; SMBG: self-monitoring of blood glucose; SMUG: self-moni-
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toring of urine glucose
Appendix 5. Effects of SMBG in patients with type 2 diabetes who are not using insulin (other
outcomes)
Within group dif-
ferences
Between group
differences3
Out-
come
Study
ID
Inter-
vention
N Mea-
sure
Sub-
scales
Range Base-
line1
End of
study1
Differ-
ence2
P value Inter-
vention
vs con-
trol
P value
be-
tween
groups4
Qual-
ity of
life
Di-
GEM
trial
2007
Control 152 EQ5D 0 to 1 0.799 ±
0.023
0.798 ±
0.034
-
0.001 (-
0.060 to
0.059)
Less in-
tensive
SMBG
150 0 to 1 0.781 ±
0.022
0.755 ±
0.024
-
0.027 (-
0.069 to
0.015)
-
0.029 (-
0.084 to
0.025)
More
inten-
sive
SMBG
151 0 to 1 0.807 ±
0.024
0.733 ±
0.024
-0.
075 (-0.
119 to -
0.031)
-
0.072 (-
0.127 to
0.017)
Kleefs-
tra
2010
Control 18 SF-36 Physi-
cal com-
ponent
0 to 100 48.5 ±
10.6
47.9 ±
7.9
Men-
tal com-
ponent
0 to 100 50.6 ±
10.6
51.6 ±
7.7
Health
change
0 to 100 46.9 ±
18.0
56.3 ±
11.2
-12.0 (-
20.9 to -
3.1)
> 0.01
SMBG 22 Physi-
cal com-
ponent
0 to 100 42.2 ±
10.4
44.3 ±
9.8
-0.0 (-5.
2 to 5.
1)
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Men-
tal com-
ponent
0 to 100 55.5 ±
7.4
53.1 ±
9.5
-1.4 (-6.
6 to 3.7)
Health
change
0 to 100 48.6 ±
10.4
44.4 ±
13.7
Much-
more
1994
Control 11 DQOL Satisfac-
tion
3.0 2.7 < 0.05
Impact 3.9 3.9
Worry-
social/
voca-
tional
4.3 4.6
Worry
diabetes
related
4.1 4.5
SMBG 12 Satisfac-
tion
3.1 2.7 < 0.05
Impact 4.0 4.1
Worry-
social/
voca-
tional
4.6 4.6
Worry
diabetes
related
4.0 4.6
Well-
being
Di-
GEM
trial
2007
Control 113 WBQ-
12
To-
tal well-
being
0 to 36 25.1 ±
6.3
25.9 ±
5.8
Nega-
tive
well-
being
0 to 12 1.5 ± 2.
1
1.3 ± 2.
0
Energy 0 to 12 6.5 ± 2.
9
6.8 ± 2.
6
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Positive
well-
being
0 to 12 7.6 ± 3.
2
8.3 ± 2.
8
Less in-
tensive
SMBG
121 To-
tal well-
being
0 to 36 24.3 ±
6.8
24.5 ±
7.0
0.38
Nega-
tive
well-
being
0 to 12 1.6 ± 2.
3
1.4 ± 2.
2
0.92
Energy 0 to 12 6.3 ± 2.
9
6.4 ± 2.
9
0.73
Positive
well-
being
0 to 12 7.6 ± 3.
2
7.6 ± 3.
4
0.20
More
inten-
sive
SMBG
105 To-
tal well-
being
0 to 36 25.2 ±
6.3
24.9 ±
6.4
0.38
Nega-
tive
well-
being
0 to 12 1.4 ± 2.
2
1.4 ± 2.
2
0.92
Energy 0 to 12 6.6 ± 2.
8
6.7 ± 2.
7
0.73
Positive
well-
being
0 to 12 7.9 ± 3.
0
7.6 ± 3.
0
0.20
Kleefs-
tra
2010
Control 18 WHO-
5
Total
score
0 to 100 71.0 ±
17.9
76.3 ±
11.4
SMBG 22 Total
score
0 to 100 68.0 ±
20.7
74.4 ±
14.5
-0.6 (-8.
2 to 7.0)
O’Kane
2008
Control 88 WBQ-
22
Depres-
sion
0 to 100 - -
Anxiety 0 to 100 - -
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Positive
well-
being
0 to 100 - -
Energy 0 to 100 - -
SMBG 96 Depres-
sion
0 to 100 - - 6.05 (2.
37)
0.01
Anxiety 0 to 100 - - 5.86 (3.
19)
0.07
Positive
well-
being
0 to 100 - - 4.16 (2.
88)
0.15
Energy 0 to 100 - - -0.84
(2.83)
0.77
SMBG
study
group
2002
Control 110 WBQ-
22
To-
tal well-
being
0 to 66 50.66 ±
9.46
52.55 ±
10.47
1.75 ±
7.33
Depres-
sion
0 to 18 3.33 ±
2.73
3.01 ±
2.61
-0.26 ±
2.23
Anxiety 0 to 18 4.88 ±
3.37
4.34 ±
3.66
-0.51 ±
3.26
Energy 0 to 12 8.17 ±
2.42
9.0 ± 2.
45
0.81 ±
2.61
Positive
well-
being
0 to 12 14.6 ±
3.14
14.91 ±
3.38
0.27 ±
2.85
SMBG 113 To-
tal well-
being
0 to 66 50.52 ±
8.47
54.03 ±
8.24
3.58 ±
7.01
0.05
Depres-
sion
0 to 18 3.18 ±
2.69
2.38 ±
2.26
-0.83 ±
2.66
0.03
Anxiety 0 to 18 5.24 ±
3.24
3.91 ±
3.0
-1.35 ±
3.34
> 0.05
Energy 0 to 12 7.91 ±
2.5
9.04 ±
2.19
1.13 ±
2.29
> 0.05
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Positive
well-
being
0 to 12 1481 ±
2.83
15.27 ±
2.8
0.49 ±
2.37
> 0.05
Patient
satis-
faction
Di-
GEM
trial
2007
Control 113 DTSQ To-
tal satis-
faction
0 to 36 29.3 ±
6.8
30.0 ±
5.3
Per-
ceived
hyper-
gly-
caemia
fre-
quency
0 to 6 1.7 ± 1.
7
1.9 ± 1.
9
Per-
ceived
hypo-
gly-
caemia
fre-
quency
0 to 6 0.6 ± 1.
2
0.7 ± 1.
3
Less in-
tensive
SMBG
121 To-
tal satis-
faction
0 to 36 29.4 ±
6.5
29.7 ±
5.6
0.93
Per-
ceived
hyper-
gly-
caemia
fre-
quency
0 to 6 1.5 ± 1.
6
2.3 ± 1.
5
0.05
Per-
ceived
hypo-
gly-
caemia
fre-
quency
0 to 6 0.7 ± 1.
3
0.7 ± 1.
2
0.97
More
inten-
sive
SMBG
105 To-
tal satis-
faction
0 to 36 29.7 ±
5.4
30.1 ±
5.5
0.93
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Per-
ceived
hyper-
gly-
caemia
fre-
quency
0 to 6 2.0 ± 1.
7
2.4 ± 1.
7
0.05
Per-
ceived
hypo-
gly-
caemia
fre-
quency
0 to 6 0.8 ± 1.
3
0.8 ± 1.
3
0.97
Kleefs-
tra
2010
Control 18 DTSQ To-
tal satis-
faction
0 to 36 30.7 ±
4.2
30.7 ±
4.0
Per-
ceived
hyper-
gly-
caemia
fre-
quency
0 to 6 2.6 ± 1.
7
1.9 ± 1.
9
Per-
ceived
hypo-
gly-
caemia
fre-
quency
0 to 6 0.0 (0.0,
1.0)
0.0 (0.0,
2.0)
SMBG 22 To-
tal satis-
faction
0 to 36 29.3 ±
4.8
32.1 ±
3.8
1.2 (-1.
6 to 4.1)
Per-
ceived
hyper-
gly-
caemia
fre-
quency
0 to 6 2.2 ± 1.
6
2.3 ± 1.
9
0.5 (-0.
8 to 1.8)
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Per-
ceived
hypo-
gly-
caemia
fre-
quency
0 to 6 1.0 (0.0,
2.5)
1.0 (0.0,
2.0)
0.3 (-0.
5 to 1.1)
O’Kane
2008
Control 88 DTSQ To-
tal satis-
faction
0 to 36 - -
SMBG 96 To-
tal satis-
faction
0 to 36 - - > 0.05
SMBG
study
group
2002
Control 110 DTSQ To-
tal satis-
faction
0 to 36 26.95 ±
6.61
30.57 ±
5.54
3.6 ± 7.
63
SMBG 113 To-
tal satis-
faction
0 to 36 27.58 ±
7.13
31.1 ±
4.78
3.52 ±
7.19
0.9
Footnotes
1 numbers are mean difference ± SD or median (Q25, Q75)
2 numbers are mean difference (95% CI) or mean difference (SD)
3 numbers are mean difference (95% CI) or b coefficient (SE)
4 P value represents a three-group comparison for DiGEM trial
“-” denotes not reported
DTSQ: diabetes treatment satisfaction questionnaire; EQ5D: EuroQol-5D; DQOL: diabetes quality of life inventory; SMBG =
self-monitoring of blood glucose; SMUG = self-monitoring of urine glucose; SF-36: Short-Form 36; WBQ-12/22: well-being
questionnaire-12/22; WHO-5: World Health Organization-5
Appendix 6. Adverse events
Study
ID
Char-
acteris-
tic1
Allen
1990
Barnett
2008
David-
son
2005
Di-
GEM
trial
2007
Durán
2010
Fran-
ciosi
2011
Font-
bonne
1989
Guerci
2003
Kleefs-
tra
2010
Much-
more
1994
O’Kane
2008
SMBG
study
group
2002
Inter-
vention
(n)
27 311 43 301 99 46 140 345 22 12 96 113
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(Continued)
Control
(n)
27 299 45 152 62 16 68 344 18 11 88 110
Deaths
(n)
- 0 0 8 0 0 - 4 0 - 0 -
Adverse
events
(n)
- 86 - - - 0 - 167 - - - -
Adverse
events
(n / %)
- 14 - - - 0 - 24 - - - -
Drop-
outs
due to
adverse
events
(n)
- 2 - - - 0 - 6 - - - -
Defini-
tions of
recorded
hypo-
gly-
caemic
episodes
• Grade
1: sus-
pected
mild
hypo
• Grade
2: sus-
pected
moder-
ate
hypo
• Grade
3: sus-
pected
severe
hypo
with
need of
third
party
assis-
tance
• Grade
• Grade
1: self-
re-
ported
hypo
with no
accom-
pany-
ing
symp-
toms
• Grade
2: mild
symp-
toms
requir-
ing
minor
inter-
vention
• Grade
3: mod-
erate
• Severe
hypo-
gly-
caemia:
requir-
ing as-
sistance
from a
third
person
•
(any)
Hypo-
gly-
caemic
episode
• Asymptomatic
hypo:
no defi-
nition
avail-
able
• Symptomatic
hypo:
no defi-
nition
avail-
able
-
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(Continued)
4: sus-
pected
severe
hypo
with
need of
medical
assis-
tance
symp-
toms
requir-
ing im-
mediate
third
party
inter-
vention
• Grade
4:
uncon-
scious
Cut-off
point
for hy-
pogly-
caemic
episode
Capil-
lary
blood
glucose
<
3mM/L
Capil-
lary
blood
glucose
<
4mM/L
- Capil-
lary
blood
glucose
< 3.3
mM/L
Capil-
lary
blood
glucose
<
3mM/L
-
Hy-
pogly-
caemic
episodes
(n)
- 117 - 90 - 0 - 78 - - 67 -
Hy-
pogly-
caemic
episodes
(%)
- 19 - 20 - 0 - 11 - - 37 -
Severe
hypo-
gly-
caemic
episodes
(n)
- 0 - 1 0 0 - 0 - - - -
Severe
hypo-
gly-
caemic
episodes
(%)
- 0 - 0 0 0 - 0 - - - -
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(Continued)
Noc-
turnal
hypo-
gly-
caemic
episodes
(n)
- 10 - - - - - - - - - -
Noc-
turnal
hypo-
gly-
caemic
episodes
(%)
- 2 - - - - - - - - - -
Footnotes
“-” denotes not reported
1 Data for adverse events could not be extracted separately for intervention and control groups
F E E D B A C K
Comment to the review by Welschen
Summary
Welschen reports some conclusions and implications for the practice that do not seem to be closely and accurately based in the results
of the review.
The conclusions of Welschen are: …self-monitoring of blood glucose (SMBG) might be effective in improving glycaemic control in
patients with type 2 diabetes who are not using insulin..….by using SMBG, patients can achieve a more individual management of
their disease and thereby a better quality of life and this might result in a decrease in consultations with the general practitioner.
In my opinion, it is unclear on what results is Welschen based to write these conclusions. In fact, after reading the results I believe the
conclusions should have been neutral or even the opposite ones. In Results Welschen wrote:
- The studies of Allen 1990 and Davidson 2005 [no efficacy of SMBG] were considered of high quality… The studies of Fontbonne
1989, Muchmore 1994 ……and Schwedes 2002 and Guerci 2003 [the only two trials reporting efficacy of the SMBG] …were
considered to be of low quality.
- Heterogeneity... Because of differences in baseline data of the patients and type of interventions between the studies, it was not possible
to perform either a meta-analysis and/or subgroup or sensitivity analyses.
- Glycaemic control measured by HbA1c… Fontbonne 1989, Muchmore 1994 and Davidson 2005 [the only one blinded and with a
high quality score] found no statistically significant differences in the decrease of HbA1c between the SMBG and the control groups…
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Schwedes 2002 [low quality] found a statistically significant difference of 0.5% in HbA1c in favour of SMBG…Guerci 2003 [low
quality] also found a statistically significant difference of 0.4% in HbA1c at the end of the study between the SMBG and control group.
- We considered that the SMBG group in Schwedes 2002 did receive a co-intervention by means of a structured counseling program
every four weeks during the intervention period. The control group only received a non-standardised counseling [see results]…….
However, because this was considered as a co-intervention, the effect of SMBG only is not clear [see Discussion].
- Guerci 2003 reported a dropout rate of more than 40% [48% in the intervention group], which was considered non-acceptable.
- In addition, there is no evidence that SMBG has a beneficial effect on fasting plasma glucose, quality of life, well-being, patient
satisfaction and number of hypoglycaemic episodes.
In medical statistics the presumption of efficacy does not exist, but it is the opposite. It starts with the null hypothesis (there are not
significant differences between an intervention [SMBG] versus other [blood glycated haemoglobin every 2-4 months]) and clinical
trials are performed to try to pull the null hypothesis down.
Welschen has failed to achieve it in her review. Her conclusions on the efficiency of the self-monitoring are based on two studies that
herself has almost rejected before for deficient quality: one because a co-intervention in favour of the group of self-monitoring (risk of
attrition bias), and the second because a clinical trial where the drop-outs and withdrawals rise up to 48 % of the participants loses
the benefit of the randomisation, of the sample size, set doubts about the internal validity and more obvious doubts about the external
validity (the applicability to the general population) of the results.
None of these inconveniences have been reported in the conclusions.
1.Coster S.Monitoring blood glucose control in diabetesmellitus: a systematic review.NHSR&DHTAProgramme.HealthTechnology
Assessment. 2000;4(12).
Reply
In our review, we tried to assess the effects of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes who are not
using insulin in order to eliminate the debate on the effectiveness of SMBG as a tool in the self-management of these patients.
Sáenz comment was that our conclusions were not based on accurate results. We respectfully disagree with Sáenz and we will argue
below that we still stick to the conclusion from our review that SMBG might improve glycaemic control.
The review of Coster 2000 (1) cannot be used as an adequate summary of the evidence for the effect of SMBG by health care
professionals, as was suggested by Sáenz, because it is out-dated and because of the inclusion of a trial with patients using insulin (Wing
1986).
Our review included all randomised controlled trials until September 2004 (2).
The direction of the effect of the combined studies is clearly in favour of SMBG and definitely not the opposite as Sáenz stated. The
absence of a statistical significant effect should not be interpret as evidence of no effect (3). Moreover, since the largest studies included
in our review found statistically significant differences suggests that the other smaller studies possibly did not include enough patients.
In our review we reported clearly that the evidence for an effect of SMBG onHbA1c was moderate, based on the overall methodological
quality of the trials. In addition, in our methods section it was described that we did not intend to exclude trials on the basis of
methodological quality criteria as suggested by Sáenz. In our discussion section, we explicitly described all methodological issues that
should be taken into account before reading definitive conclusions.
We concluded that SMBG might be effective which in our opinion implies that the conclusions should be interpreted with caution.
Because of the remaining uncertainty we also recommend a high quality randomised controlled trial to provide more solid evidence
of the effect of SMBG on a large range of outcomes. We believe that, apart from glycaemic control, quality of life, well-being and
patient satisfaction are all very important outcome measures. Unfortunately, these outcome measures where not measured in most of
the studies and therefore we could not draw conclusions on these important outcomes.
With respect to our review, we conclude that we paid sufficient attention to all the limitations in the available evidence in our review.
In our view it is too early to reject a potentially helpful tool for patients with diabetes who need to incorporate their chronic disease
into their daily lives.
Laura MC Welschen, MSc
Evelien Bloemendal, MSc
Giel Nijpels, MD, PhD
Jacqueline M. Dekker, PhD
Robert J. Heine, MD, PhD
Wim A.B. Stalman, MD, PhD
Lex M. Bouter, PhD
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Comments to the review by Malanda et al, 6 March 2012
Summary
In the review, the authors conclude that “the overall effect of self-monitoring of blood glucose on glycaemic control in patients with type
2 diabetes who are not using insulin is small up to six months after initiation and subsides after 12 months” [1]. For the meta-analysis
on the effects of SMBG vs. control in patients with a diabetes duration greater than one year, nine studies with a six months follow-
up (2324 patients) were included. For the corresponding 12 months follow-up, two of the 9 studies (493 patients) were included. The
HbA1c reduction of -0.3% (-0.4 to -0.1) at six months [1] was statistically significant and in view of UKPDS, in which a 1% reduction
in HbA1c was associated with a 37% decrease in risk for microvascular complications and a 21% decrease in the risk of any end point or
death related to diabetes [2], a statistically significant reduction of HbA1c 0.3% at six months should be recognized and valued for the
treatment of type 2 diabetes. We feel it is a limitation of the analysis that only two studies, DiGEM trial and ZODIAC-17 [3,4], were
included in the 12 month follow-up meta-analysis. In the analysis a non-significant decrease in HbA1c (-0.13% (-0.13 to -0.04)) was
reported. Both studies, furthermore, are characterized by several limitations, which need to be considered: In the DiGEM trial, HbA1c
values of the patients in the three different groups ranged from 7.41% to 7.53%. Inclusion of patients with a stable and relatively good
metabolic control at entry into the study may have attenuated the need for a modification or intensification of treatment within any of
the three groups. In the study, therefore, the usage of oral antidiabetic agents (OADs) was increased only in less than one-third of the
patients. In both the less intensive and the more intensive intervention groups, OADs were not increased more frequently as compared
with the control group (29% and 32% vs 30%). No specific algorithm for modification of treatment plans was mentioned. It is also
noteworthy, that the enrolled patients were a highly selected population (453 patients out of 2986 total eligible ones) [5]. ZODIAC-
17 is a small Dutch study, in which only 22 patients were included in the SMBG group, of whom 17 performed at least 80% of the
requested glucose measurements. The authors of the study mention in the discussion the sample size as an important limitation of the
study. In the study, structured testing of blood glucose was not applied and any information on modification of treatment is missing
[3]. We, therefore, would like to point out that due to the limitations of the two studies the conclusions given in the Cochrane analysis
for the 12 months follow-up are not warranted. The fact that recent prospective and randomized studies which demonstrated benefits
of structured self-monitoring of blood glucose approaches in non-insulin treated type 2 diabetes mellitus, e.g. STeP-study, St. Carlos
study and ROSES [6-8], report significant outcome results opposite to your meta-analysis, further limits your conclusions.
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Reply
In our review1 , we explored whether newer trials with possible good or improved methodological quality and design, published after
Welschen et al.2 would provide new evidence of the effects of self-monitoring of blood glucose on glycaemic control in patients with
type 2 diabetes mellitus who are not using insulin.
We thank Schnell et al. for their comments regarding the clinical relevance of a 0.3% reduction in HbA1c after six months of self blood
glucose monitoring and the limited amount of available evidence for longer-term effects in patients with longer duration of diabetes.
In our discussion we have acknowledged that the reduction in HbA1c of 0.3% observed in the subgroup of patients with diabetes
duration of at least one-year and a six month follow-up is statistically significant. Indeed, in the UKPDS the observed difference of
7.9% and 7.0 % between the control and the intervention groups was associated with considerably reduced morbidity and mortality.
Since then, a reduction of 0.5% had generally been accepted to be of clinical relevance3 and most included and more recent trials
have based their power on this4−7. These expected effects were not achieved, and compared to the expectations, a reduction of 0.3%
is relatively small.
We agree that from a public health perspective, small reductions might have an important role - however, under the condition that
these are achieved at a large scale and at low cost. For SMBG so far, this is not the case3;8.
With respect to the limited number of longer-term studies, we like to stress that our review was performed under the stringent conditions
of the Cochrane Collaboration. Therefore, an extensive assessment of risk of bias was performed following previously determined
guidelines. Both the DiGEM trial and ZODIAC-174;9 were assessed with low risk of bias on most domains, indicating proper internal
validity.
Both trials assessed and compared SMBG effects with patients not using SMBG in an existing usual diabetes care structure and with
oral glycaemic titration schedules in line with the national diabetes guidelines at the time the study was performed9;10.
The subgroup under critique was a-priori defined, was designed to limit clinical heterogeneity and met the widely acknowledged
GRADE working group criteria11. The results from the 12-months analysis show an estimate of the effect comparable to the estimate
found in the 12 months analysis ([-0.4 to -0.1] vs. [-0.3 to 0.04]) indicating a similar precision in effect. Further, a best-evidence
synthesis would have shown a similar non-significant direction in effect.
Summarized, we stress that the 12-months analysis is correctly performed, that included studies met the highest criteria for inclusion
and thus results are valid.
We agree that patients in the specific subgroup weremoderately controlled (range 7.4% to 7.7%) and therefore potentially less susceptive
to benefit from SMBG. However, this was according to the predefined cut points. Furthermore, in a recent published individual patient
data meta-analysis12 the effects of SMBG did not differ between groups with different levels of baseline entry HbA1c.
All studies that were mentioned to demonstrate benefits of structured SMBG were indeed included in our review and taken up in the
appropriate subgroup analyses, except for the STeP study5. This study did not comply with our inclusion criteria having a control-
group with access to self-monitoring. The ROSES-study7 is included in the subgroup of patients with a diabetes duration of one year
and a follow-up of six months; the St. Carlos study13 is taken up in the subgroup of newly diagnosed patients with a follow-up of six
and 12 months. Conclusions resulting from these subgroup analyses are not comparable with the conclusion of the subgroup under
critique and therefore do not limit our analysis.
Thus, though we acknowledge the amount of available evidence for longer-term effect in patients with diabetes duration of over one
year is limited, predefined protocols were followed leading to the inclusion of good quality studies.
At the present state of evidence, we feel our conclusions are justified. Of course, in future studies, with more innovative interventions,
extended behavioural strategies or in additional subgroups, SMBGmay be proven beneficial on the long-term. Still, these future studies
have to prove cost-effectiveness. As we stated in our discussion: translation into practice of the presented results is difficult, and should
be done with caution.
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Date Event Description
5 April 2012 Feedback has been incorporated New feedback received on 6 March 2012, authors replied on 12 March 2012
H I S T O R Y
Protocol first published: Issue 4, 2004
Review first published: Issue 2, 2005
Date Event Description
8 December 2011 New search has been performed Updated with six new trials (Barnett 2008; DiGEM
trial 2007;Durán 2010; Franciosi 2011; Kleefstra 2010;
O’Kane 2008)
8 December 2011 New citation required and conclusions have changed Conclusions were changed.
20 October 2010 New search has been performed Review has been updated with 5 new trials. Conclusions
have been changed. Four authors have left the team and
three others have joined
1 January 2009 Amended Uriëll Malanda, Sandra Bot and Ingrid Riphagen has
joined the review team
Evelien Bloemendal, Robert Jan Heine, Wim Stalman
and Lex Bouter have left the team
Uriëll Malanda is the new contact person: u.ma-
landa@vumc.nl
C O N T R I B U T I O N S O F A U T H O R S
URILL MALANDA: wrote the draft of this review that was commented on and discussed by LAURA WELSCHEN, INGRID
RIPHAGEN, GIEL NIJPELS, JACQUELINE DEKKER and SANDRA BOT.
INGRID RIPHAGEN: performed the searches.
URILLMALANDA and LAURAWELSCHEN: independently inspected the titles and abstracts of the references identified to evaluate
their potential eligibility.
URILL MALANDA and LAURA WELSCHEN: independently assessed the risk of bias of the relevant trials and performed data
extraction and data entry.
URILL MALANDA, LAURA WELSCHEN, INGRID RIPHAGEN, JACQUELINE DEKKER, GIEL NIJPELS and SANDRA
BOT: interpreted the findings and helped writing the final manuscript.
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D E C L A R A T I O N S O F I N T E R E S T
URILL MALANDA, JACQUELINE DEKKER, GIEL NIJPELS and SANDRA BOT all take part in an ongoing study on the topic
of interest of this review.
S O U R C E S O F S U P P O R T
Internal sources
• EMGO Institute for Health and Care Research, Netherlands.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This section relates to the differences between the first review (Welschen 2005a) and the present review-update (Malanda 2011).
1. Four authors have left the team and three others have joined.
2. Because HbA1c reflects a more constant view of glycaemic control over time, we believe that changes in fasting plasma glucose
are of less value for assessing the effect of self-monitoring of blood glucose (SMBG). We therefore assessed effects on fasting plasma
glucose level as a secondary outcome whereas this was a primary outcome in the first review.
3. We have added PsycInfo to our search strategy because studies investigating the effect of SMBG on quality of life or well-being
might not be published in regular medical databases.
4. The mandatory Cochrane ’Risk of Bias’ tool has replaced the Amsterdam-Maastricht list.
5. Review has been updated with six new trials (Barnett 2008; DiGEM trial 2007; Durán 2010; Franciosi 2011; Kleefstra 2010;
O’Kane 2008).
6. Addition of six new studies made it possible to perform pooled random-effects subgroup analyses on the basis of diabetes
duration and follow-up.
7. Conclusions could be drawn on the effect of SMBG on glycaemic control for subgroups and for patient satisfaction, general
well-being or general health-related quality of life.
8. Conclusions have been changed
I N D E X T E R M S
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Medical Subject Headings (MeSH)
∗Blood Glucose Self-Monitoring [methods]; Diabetes Mellitus, Type 2 [∗blood; urine]; Hyperglycemia [prevention & control]; Hy-
poglycemic Agents [administration & dosage]; Insulin [administration & dosage]; Quality of Life; Randomized Controlled Trials as
Topic
MeSH check words
Humans
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